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Abstract 
Salbutamol is a Beta-2-agonist, commonly prescribed for the prevention and 
reversal of Exercise induced asthma (EIA). The purpose of this study was to compare 
the efficacy of a spacer device in the delivery of salbutamol for the prevention of EIA. 
Thirteen confinned asthmatic subjects ( 10 female and 3 male), completed 3 exercise test 
sessions consisting of three treatments a) Ventolin via MDI (metered dose inhaler) and 
placebo via spacer, b) Ventolin via spacer and placebo via MDI and c) Placebo via 
spacer and MDI, randomly administered utilising a single blind, cross-over design. 
Following treatment, subjects completed an asthmogenic physical challenge (8-minute, 
graded treadmill run at 75-85% predicted heart rate maximum). The lung function 
variables: FEV1, FVC, PEFR, FEFso, and FEF2s-1s were recorded pre-treatment, pre-
exercise and 0,3,5,7,10,20 and 30 minutes post-exercise. Of the 13 subjects, only 7 
demonstrated sufficient decrement in FEV 1 to be classified as EIA. In the subjects who 
demonstrated EIA, no significant differences were found for post-exercise lung function 
measures between the spacer and MDI mean scores. Administration of salbutamol via 
the spacer resulted in significant improvements over the placebo scores in MEF50 and 
FEF2s-1s, and significant test/time interactions for FVC and FEV1, however the MDI 
scores were not significantly different to the placebo. The findings were congruent with 
previous findings which suggest that spacer delivery offers no significant advantage in 
preventing EIA in subjects who are skilled in MDI administration techniques. The 
inability to induce EIA in 6 of the 13 subjects may relate to the high lability scores 
recorded for several subjects suggesting that bronchoconstriction was evident prior to 
testing. This may have been due to the high pollen count recorded during testing. 
Secondly, the asthmogenic nature of the testing environment may have been hindered 
V 
due to the high level of fluctuation in the relative humidity recorded for each test. 
Although conclusions have been made concerning spacer efficacy, this study should be 
replicated under more asthmogenic conditions to confirm the findings of this study. 
VI 
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The phenomena of asthma, otherwise known as 'airways narrowing', has been 
recognised and documented for nearly 19 centuries. Today, asthma is one of the most 
common respiratory diseases with at least 10% of the Australian adult population 
affected and 20% of the adolescent population (Rees & Price, 1989). It is estimated that 
30% of the population will exhibit asthma type symptoms at some time during their lives 
(National Asthma Campaign, 1996). The relationship between asthma and exercise has 
been described as being 'paradoxical' (Morton & Fitch, cited in Skinner, 1993, p.211) in 
that although exercise can improve the symptoms of asthma (Cox, Van-Herwaarden, 
Folgering, & Binkhorst, 1988), it has the potential to induce several clinical signs and 
symptoms of bronchoconstriction. (Chen & Horton, 1977) 
Exercise-induced asthma (EIA) is a term used to describe the transitory increase in 
airway resistance which follows vigorous exercise in most asthmatic individuals 
(Anderson, 1988). EIA is categorised within the broad definition of asthma in that the 
airway narrowing process is similar in action to that of other asthmatic bronchospasms. 
However the severity and duration are usually reduced. (National Asthma Campaign, 
1996). 
Prevention of EIA is now achieved through pre-exercise medication which is 
taken in unison with additional medication for the control of general asthma. Inhaled 
Ventolin™ is the most readily used form of the Beta-2-agonist, salbutamol, a 
bronchodilator which aids in the non-ergogenic reduction of the symptoms of EIA that 
disadvantage asthmatic athletes. Few studies have been undertaken into the delivery of 
salbutamol. For elite and non-elite athletes, the question still persists over whether 
metered dose inhalers (MDI's) or spacers present the best delivery options. The spacer is a 
chamber designed to hold the spray of medication from an MDI before it is inhaled. This 
theoretically overcomes the problem that many asthmatics, especially young children, 
have in coordinating the deep inhalation with the actuation of the MDI. Both have 
advantages and disadvantages, yet no study has been done on the efficacy of each with 
· regard to the effects on lung function pre and post-exercise with asthmatics prone to 
exercise-induced attacks. The purpose of this study is to investigate what consequential 
differences exist between the spacer delivery and metered dose delivery of salbutamol 
with reference to EIA and relevant lung function measures. Falls in the forced expiratory 
volume in the first second (FEV1) will be the primary measure to assess if EIA has 
occurred as it is widely considered the benchmark in pulmonary function indication. 
1.2 Significance of the Study 
Asthmatics perform exercise and sport with a significant respiratory 
disadvantage. It is important therefore, to examine all possible means of allowing the 
asthmatic to participate on an equal basis with the non-asthmatic and without suffering 
the discomfort and performance limitations produced by EIA. More importantly, the 
benefits of reducing this discomfort in asthmatic sufferers whilst exercising may see a 
renewal in exercise thus having a large improvement on lifestyle and overall health. 
This study will generate a greater understanding of the delivery of salbutamol to 
such individuals, so that when participating in sport, respiratory equality between 
competitors is approached or achieved and discomfort that bronchospasm produces 
minimised or even prevented. 
2 
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1.3 Research Questions 
The purpose of this study was to determine whether the use of a 'spacer' to 
deliver salbutamol (Ventolin™) provides better protection from exercise-induced 
asthma than delivery via a metered dose inhaler (MDI). The specific research questions 
concerning changes in selected lung function measures after exercise are: 
1. Does a spacer assisted pre-exercise inhalation of salbutamol increase post-
exercise Forced Expiratory Volume in one second (FEV 1) in comparison to the 
metered dose inhalation method using a MDL 
2. Does a spacer assisted pre-exercise inhalation of salbutamol increase post-
exercise Peak Expiratory Flow Rate (PEFR) in comparison to the metered dose 
inhalation method using a MDI? 
3. Does a spacer assisted pre-exercise inhalation of salbutamol increase post-
exercise Forced Vital Capacity (FVC) in comparison to the metered dose 
inhalation method using a MDI? 
4. Does a spacer assisted pre-exercise inhalation of salbutamol increase post-
exercise Forced Expiratory Flow rate ( after 50% of the forced vital capacity 
manoeuvre is complete) and Forced Expiratory Flow rate (during the middle half 
of the forced vital capacity manoeuvre) in comparison to the metered dose 
inhalation method using a MDL (MEF50 & FEF25_75) 
3 
--
1.4 Definition of Terms 
Salbutamol The name given to the most widely used form of the beta-2-agonist drug which 
is used as a reliever for asthma patients and as a preventer of EIA. Retailed as Ventolin ™ 
Ventolin The trade name of the form of salbutamol manufactured by Glaxo 
Pharmaceuticals company. The most commonly used form of salbutamol. 
Exercise-induced asthma (EIA) Asthma triggered by physical activity 
Forced Vital Capacity (FVC) Vital capacity when performed with a maximally forced 
expiratory effort following a maximal inhalation. 
Forced Expiratory Volume in 1 second 
second of a forced vital capacity manoeuvre 
(FEV1) The volume of air exhaled in the first 1 
Forced Expiratory Volume 1 % 
FVC; FEV1 +FVC x 100 
(FEV 1 % ) The FEV 1 value expressed as a percentage of 
Peak Expiratory Flow Rate (PEFR) The highest forced expiratory flow rate 
measured during a forced vital capacity manoeuvre. 
Forced Expiratory Flow rate (25%-75%) (FEF25-75) Mean forced expiratory flow rate 
during the middle half of the forced vital capacity manoeuvre. 
Forced or Maximal expiratory flow rate (50%) (FEF50 or MEF50) Forced expiratory 
flow rate when 50% of FVC has been exhaled during a forced vital capacity manoeuvre. 
Metered Dose Inhaler (MDI). An aerosol container used to administer a fixed dose of inhaled 
medication. 
Spacer A clear plastic tube used to aid in the delivery of inhaled medication. 
Bronchial Lability The maximum post-exercise percent increase plus the maximum post-


















Analysis of Variance 
Blood pressure 
Exercise-Induced Asthma 
Forced Vital Capacity 
Forced Expiratory Volume during the first second of a FVC 
maneuvre 
FEV 1 + FVC expressed as a percentage 
Forced Expiratory Flow rate in the middle half of a FVC 
maneuvre. 
Maximal Expiratory Flow rate after 50% of the FVC maneuvre 
is complete. 
Peak Expiratory Flow Rate 
Heart Rate 
Maximum heart rate 
Metered Dose Inhaler 
Respiratory Heat Loss 
Respiratory Water Loss 
Rate of Perceived Breathlessness. 
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CHAPTER TWO 
2.0 Literature Review 
2.1 Asthma 
Asthma is defined as being; 
"A chronic disorder of the airways in which many cells play a role. In 
susceptible individuals, this inflammation causes symptoms which are usually 
associated with widespread but variable airflow obstruction that is often reversible 
either spontaneously or with treatment and it also causes an associated increase in 
airway responsiveness to a variety of stimulii." (National, heart, lung and blood 
institute, 1992) 
Bundgaard, ( 1985) states that asthma is a disease characterised by airways inflammation 
typified by mucosal infiltration with inflammatory cells, thickened airway walls, spasms 
of bronchial smooth muscle, oedema, hypertrophy of glands and smooth muscle, 
damaged epithelium and increased production of mucous. Although these symptoms 
vary in response to therapy, the underlying inflammation persists. 
Swimbum, (1976) adds that the disease is characterised by intermittent attacks with 
fluctuating severity. Anderson (1988, p.1156) supports this notion by terming asthma as 
'transitory' thus placing emphasis on the short-term nature of the diseases symptoms. 
2.1.1 Population Particulars of Asthma 
Asthma is one of the most common respiratory diseases in modem industrialised 
nations affecting between 4-16% of the population (Morton, Fitch & Hahn 1981 ). Since 
the early 1980' s, the incidence of asthma within Australia has increased at a rate higher 
than that accountable for population increases, with Australians and New Zealanders 
having the highest rate of asthma in the Westernised world. Swimbum, (1976) suggests 
that within these populations, males have a higher incidence of asthma than females at a 
ratio of 7:3. Anderson (1986) argues that this ratio would be more realistic at 3:2, with 
6 
young children having the highest rate. Later in life, this figure is reversed, with 
females over the age of 55 having the higher rate than males of the same age. 
2.2 Exercise-induced asthma 
Exercise Induced Asthma is defined as being any asthmatic episode provoked by 
the incidence of vigorous physical activity (Katz & Pierson, 1988). EIA is characterised 
by an increase in airway resistance that occurs after 6 to 8 minutes of strenuous exercise 
and appears in 70% to 80% of asthma patients. Of this group, 70% will require pre-
exercise medication. The majority of EIA sufferers recover spontaneously, with little 
after-effect from exercise (Anderson 1986). Bundgaard (1985, p. 256), states that EIA 
should be referred to as 'hyperpnoea-induced asthma' due to the fact that EIA is 
facilitated by the heavy breathing associated with physical activity. 
2.2.1 Mechanisms of Exercise-Induced Asthma 
2.2.1.1 Previous Findings 
In 1864, speculation existed on the effects cold air had on the stimulation of 
nervous system irritability that caused asthma (Katz and Pierson, 1988). Since then, 
research has been centred upon the causes of asthma with particular emphasis on 
respiratory response to airway cooling and drying. Engstrom, Karlberg, and Kraepelein 
(1960) found that with the onset of EIA there was a significant difference in lung 
function measurements between normal and asthmatic children. Jones, Buston, and 
Wharton (1962) showed that a correlation existed between the type and duration of 
exercise and the severity of the asthma attack. Since these discoveries, research was 
undertaken into all forms of exercise including stairways, treadmills, cycle-ergometers 
and swimming to give a greater understanding of the mechanisms and attributes ofEIA. 
7 
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Unfortunately, these tests caused greater contradiction with many conflicting results 
causing discrepancies with past and present findings. Katz and Pierson ( 1988) state that 
from these findings, EIA was related to a plethora of disorders including; hypoxemia, 
hypocapnia, acidosis, bicarbonate decrease, and reflex bronchial apposition. 
Argument exists that asthma is caused by hyperventilation (Bundgaard, 1985) which 
contradicts Beaudry, Wise and Seely (1967) and McFadden and Lyon's (1968) findings 
that hypoxemia is a more probable cause of EIA. 
Hypocapnia or depressed plasma carbon dioxide contradicts the hypoxemia theory and 
is argued against by Sterling ( 1968) stating that changes in partial pressures of carbon 
dioxide cause respiratory resistance in all individuals whether they suffer from asthma 
or not. Vassalo, Gee, and Domm, (1972) argue that metabolic acidosis is associated 
with increased airway resistance in asthmatics and normal subjects. This process is 
given credence due to the theory that an increase in arterial hydrogen ions occurs with a 
corresponding fall in bicarbonate and partial pressures of oxygen within the respiratory 
system. This function is concomitant with the processes described by Anderson (1986), 
where respiratory water loss may increase osmolarity and concentrations of the pre-
mentioned substrates. Today, argument is centred upon the theories that EIA is 
triggered by either; respiratory water loss (RWL) or respiratory heat loss (RHL), both of 
which are discussed later. 
2.2.1.2 Influence of Exercise on the Respiratory System 
During the first few minutes of exercise, bronchodilation occurs. Due to this 
increase in air space within the upper respiratory system, peak expiratory flow rate 
(PEFR) and forced expiratory volume in one second (FEV 1) increase (Anderson, 1986). 
As the exercise intensity increases, there is an increase in minute ventilation resulting in 
8 
an increase in heat and water loss from the mucosal surf ace of the respiratory tract. 
(Anderson & Schoeffel, 1982). This process, first demonstrated by Otis ( 1964 ), showed 
that under resting conditions, this heat and water loss only accounted for 10% of the 
total heat and water loss from the body. During exercise, ventilation can increase by up 
to 40 times (5 litres/min up to 200 litres/min) with water and heat loss from the airways 
being markedly increased. It is argued by Novinski, Bar-Yishay, Gur and Godfrey 
( 1987), that RHL is the triggering factor in EIA. A theory initially manifested by Deal, 
McFadden, Ingram and Jaeger, (1979), and reaffirmed by McFadden (1983). 
According to Anderson ( 1986), the temperature of the inhaled air is not critical 
to the EIA response. She states that the rate of water loss from the mucosal wall of the 
respiratory tract, otherwise known as respiratory water loss (RWL), is of far greater in 
importance to the triggering of EIA. A theory widely supported within the academic 
community. (Hahn, Anderson, Morton, Black & Fitch, 1984; Anderson, Schoeffel, 
Follet, Perry, Daviskas, & Kendall, 1982) 
2.2.1.3 Respiratory Response to EIA 
There is little difference in the asthma bronchoconstriction caused by exercise 
and that induced by other pathophysiological factors such as dust and pollen allergies. 
According to Hahn (1985) the incidence of EIA is directly related to the type of exercise 
undertaken and the environmental factors associated with it. Jones, Buston, and 
Wharton (1962) state that the potency of exercise as a stimulus is an integrated function 
of its duration, intensity and type. However, later research has proven that external 
factors such as temperature and humidity also play a major role in the severity of an 
asthmatic attack. 
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According to Godfrey (1975), EIA occurs after exercise has ceased and peaks in 
severity at 5 to 10 minutes post-exercise. Some asthmatics must cease activity during 
exercise, however the majority demonstrate bronchoconstriction post-exercise. EIA is 
initiated by the abnormally high rate of water and heat loss from the airways when 
conditioning large volumes of air in a relatively short period of time. According to 
Anderson ( 1986), the increase in respiratory airflow associated with intense exercise 
causes a high rate of water loss from the lining of the respiratory tract leading to greater 
osmolarity of the periciliary fluid. This evaporative process can instigate a 
bronchocontsrictive reaction. Many researchers argue to the contrary stating that heat 
loss through airway cooling is the primary trigger of an EIA attack (Deal, McFadden, 
Ingram & Jaeger 1979). Katz and Pierson (1988) support Anderson by stating that 
airway cooling in children can be as low as 4% of the total temperature change between 
inspired and expired air (with ambient temperatures above 37° celcius) thus supporting 
the argument that more than just airway cooling is needed for EIA. The actual process 
by which an increase in osmolarity and or a reduction in temperature leads to a 
contraction of bronchial smooth muscle is not known (Anderson, 1985). However 
several theories exist on the subject. As osmolarity of the lining fluid of the respiratory 
tract increase, reflex bronchoconstriction occurs mediated by the parasympathetic 
nervous system and the release of substances that contract bronchial smooth muscle, 
either directly or via the vagus nerve (Anderson, 1986). According to Togias, Naclerio, 
Proud, Fish, Adkinson, Kagey-Sobotka, Norman and Lichtenstein ( 1985), this process 
can increase the release of histamine from mast cells within the respiratory mucosa. 
They add that this local release of inflammatory mediators can cause localised 
respiratory tract dysfunction. Contradiction to this theory is supplied by O'Cain, 
Dowling, Slutsky, Hensley, Strohl, McFadden and Ingram, (1980), who debate that this 
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constrictive process is due to airway cooling not osmolarity and that mast cell mediator 
release due to hyperventilation is not a major effector mechanism in either normal or 
asthmatic bronchoconstriction. Figure 2.1 shows the general reaction that mast cells 
have to exercise and how the released mediators are in contradiction to catecholamines 
that aids in airway dilation. This explains the initial dilatory response exercise has on 
the airway due to the time differences displayed in the release of catecholamine in 
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Figure 2.1. Hypothetical pathways concerned in Exercise-induced Asthma. 
(Godfrey, Silverman and Anderson, 1973, p.199) 
Questions still remain as to how the inflammatory mediators reach the smooth 
muscle, however, it has been reported that this may be facilitated by a change in 
permeability of the bronchial mucosa brought about by the fore-mentioned stimulii 
Anderson ( 1986). The activity of mast cells can also lead to the release of leukotrienes 
from epithelial cells, that in tum enhance the release and action of other mediators from 
the mast cells in the sub-mucosa. 
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2.2.1.4 Pulmonary Function Response to EIA 
According to Eggleston, Kagey-Sabotka, Schleimer & Lichtenstein (1984), 
hyperosmolar fluid surrounding mast cells trigger the release of inflammatory mediators 
including histamines, causing a subsequential cascade of other immunological events 
that leads to bronchoconstriction. The effects on lung function are drastic, with 
difficulty in breathing being most prevalent in the exhalation phase of the respiratory 
cycle. Exercise often, but not always, induces an initial bronchodilation which is 
maintained throughout the exercise period (Fig. 2.2). After the cessation of the exercise, 
bronchospasm ensues, and lung function reaches its lowest level after 3 to 5 minutes in 
children and 5 to 7 minutes in adults (Weiss, Segal, & Stein 1985). For the purpose of 
this study, quantification of EIA was indexed using percent post-exercise fall in FEY 1 
of 10%. Figure 2.2 shows two possible expected trends for the PEFR in asthmatic 
subjects after an 8-minute exercise challenge. Figure 2.3, shows the expected trends for 
FEY 1 after a similar exercise protocol. Both graphs show normal and asthmatic results. 
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Figure 2.2. Typical PEFR response in asthmatic and non-asthmatic subjects. 
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Figure 2.3 . Typical effects of exercise on FEY 1 in normal and asthmatic subjects. 
(Hahn, 1985, p.4) 
2.2.2 Current treatment 
Asthmatics participate in a wide range of sports and at all levels. According to 
Hahn (1985), the type of treatment received is dependent on type and severity of the 
asthma suffered. EIA has several specific treatments which are presented in Table 2.1. 
Today, salbutamol is the most widely used anti-asthma drug available. Salbutamol is a 
Beta-2 agonist that has a selective stimulant action on beta-receptors in bronchial 
muscle (Hill, Davies & Geary, 1976). Howarth, Durham, Lee, Kay, Church and 
Holgate ( 1985) state that albuterol (US equivalent of salbutamol) inhibits the mast cell 
histamine release associated with an asthma attack. It is also reported that inhaled 
salbutamol is of greater effect in preventing EIA than the orally taken form (Bloomfield, 
Carmichael, Petrie, Jewell and Crompton, 1979). While inhaled salbutamol is permitted 
by the International Olympic Medical Commission, the oral route of administration is 
forbidden. 
Boulet, Turcotte and Tennina (1989) demonstrated that salbutamol gave the 
highest level of protection against all forms of asthma and prevented EIA to a greater 
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degree than other popular drugs (Cromoglycate and Ipratropium). Not only is 
salbutamol effective in preventing EIA, research shows that there is little or no tolerance 
or resistance generated by the asthmatic who uses the drug on a regular basis (Harvey, 
Baldwin, Wood, Alberti and Tattersfield 1981 ). Thus making it a suitable drug for EIA 
study concerned with delivery methods of the drug and the effects different delivery 
systems has on the severity of EIA. 
Table 2.1. 




















2.2.3 Relevant Studies 
Administration Effects Duration 
Inhaled or orally Decreases severity 2 hours 
taken. of asthma attack 
prior to ex. (5-10 
mins) or day before 
for pill. 
Oral (10-20µg) 
90 mins prior 
Inhalation of dried 
powder. 
5 minutes prior 








protection of EIA 
Similar to Beta 2. 





< 5 hours. 
Immediate to 1 
hour 
+ 
Past studies into EIA, have explored the range of 'bronchial }ability' in normal 
subjects and asthmatics. Non-asthmatic individuals usually demonstrate an average rise 
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in peak flow during exercise of 3 to 4% with a maximal post exercise drop of up to 10% 
(Silverman and Anderson 1972). A study by Burr, Eldridge and Borysiewicz (1974) 
found that 89% of asthmatic subjects had a fall in PEFR greater than 10%. For the 
purpose of this study, Anderson's definition of EIA has been used with FEV 1 and PEFR 
declines greater than 10% post-exercise being considered. With regard to 
reproducibility, Godfrey, Silverman and Anderson (1973) found that repeated tests 
within 1 week intervals had average coefficient variations in pulmonary function of 
21 %. This was caused by changes in the sensitivity of the asthmatic to exercise rather 
than experimental error whilst conducting the tests. 
2.2.3.1 Provocation of EIA via Running. 
Running is the most widely used physical challenge in attempting to produce 
EIA. Fitch and Morton ( 1971) demonstrated that running causes more asthma 
provocation than cycling and swimming. Anderson, Connolly, and Godfrey (1971) 
confirmed this finding by stating that the asthmogenic nature of running is far more 
effective in generating bronchoconstriction than most other modes of exercise. Several 
studies have demonstrated that an 8-minute exercise challenges produce the highest rate 
of asthma (Figure 2.4). Godfrey in Dempsey and Reed (1977) found that in many 
asthmatic patients, continuation of exercise for more than 8 minutes causes progressive 
reduction in the severity of EIA. Silverman and Anderson ( 1972) found that such 
declines in the magnitude of the airway's response can occur when prolonging the 
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Figure 2.4. The effect of duration of exercise on asthma induced by treadmill running. 
(Godfrey, Silverman and Anderson, 1973, p.201). 
2.2.4 Delivery of salbutamol 
Past research into the delivery of salbutamol for the prevention of asthma has 
been based primarily on optimal inhaler technique, deposition patterns of inhaled drug 
using different inhaler devices and the effects different drugs and drug forms have on 
lung function. As mentioned earlier, research into the area of EIA has been relatively 
limited and although many related studies have been accomplished in the area of 
asthma, these findings cannot be transferred or linked to the more specific EIA therefore 
leaving a small void of information. To date, the nebulizer technique of delivering 
aerosol medication to the lungs has been considered the most effective method of 
delivery, however it is quite impractical (Devadason & Le Soeuf, 1992) 
Delivery of salbutamol is achieved in the most efficient way through the use of the MDI 
and 'spacer'. The MDI is a dose-controlled mechanism that delivers lOOµg of 
salbutamol in a dried powder form. The spacer is a clear plastic tube with an insertion 
at one end for an MDI and a uni-directional valve mouth-piece at the other. The 
medication (salbutamol) is fired into the chamber and then inhaled over several 
respiratory cycles. Morton and Fitch (1992) state that the device overcomes the 
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requirement for co-ordination of the actuation of the MDI with the inhalation phase. 
The problem of MDI misuse is extensive due to the number of differing inhalation 
techniques and the relatively high level of coordination required to effectively inhale the 
medication (Hindle, Newton and Chrystyn 1993). Gurwitz, Mindorff, Levison and 
Reilly (1983) found that incorrect inhalation technique can be traced back to childhood 
where the ratio of equally effective oral and inhaled doses in children is about 25: 1. 
Appendix C shows the instructions that prompted research by Epstein, Manning, Ashley 
and Corey ( 1979) who found that most adults with asthma are unable to perform all of 
the manuevres correctly. Even after extensive training, 14% of all asthmatics totally 
misuse their inhalers (Patterson & Crompton 1976). Crompton (1984) placed this 
percentage at above 50% when referring to the coordination of inhalation with MDI 
actuation. This poor use or misuse of the MDI can lead to a reduction in the therapeutic 
efficacy of inhaled bronchodilators due to inadequate airway deposition of the 
medication. (Orehek, Gayrard, Grimaud & Charpin 1976) 
By using the spacer, a greater lung deposition of the medication is achievable. 
According to Rivlin, Mindorff, Reilly and Levison, (1984), this delivery system is 
significantly more effective in delivering aerosol drug to the lungs. The common 
problem of fast inhalation coupled with poor hand lung coordination whilst using an 
MDI is overcome by use of a spacer device leading to greater deposition of medication 
within the lung (Newman, Clarke, Talaee & Clarke 1989). A study conducted by 
Newman, Millar, Lennard-Jones, Moren and Clarke (1984) found that a large volume 
spacer deposited 21 % of the medication into the lungs and 16% in the oropharynx, with 
about 56% remaining in the spacer. Without a spacer, only 10-15% is deposited in the 
lungs and 70-80% on the oropharynx. The benefits of spacer use are supported by 
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Cushley, Lewis and Tatterfield (1983) and Tobin, Jenouri, Donta, Kim, Watson and 
Sackner (1982) who both argue that the spacer device not only aids in the delivery of 
drug to the lung but reduces the waste caused by poor MDI inhalation techniques. 
Theoretically, by slowing aerosol particle speed during the inhalation phase of 
MDI actuation, the spacer allows greater lung deposition by preventing the drug from 
depositing at the back of the throat and being swallowed as shown in Figure 2.5 
(Gurwitz, Levison, Mindorff, Reilly & Worsley, 1983). However, more recent research 
questions the spacer's credentials. 
Figure 2.5. Typical deposition patterns for the MDI alone (left) and for MDI with 
spacer attachment (right). 
(Newman, Millar, Lennard-Jones, Moren & Clarke. 1984, p.939) 
Konig ( 1985) refers to spacers as gimmicks and argues that they are neither a 
breakthrough nor aid in the drug delivery process for the majority of asthmatic patients. 
Barry and O'Callaghan (1994) noted similar delivery patterns when comparing the 
inhalation of aerosol drug from a Volumatic™ spacer device to an MDI. However, they 
did record a lower oropharyngeal deposition with the use of the spacer, yet there was no 
significant difference between the 2 devices with regard to lung deposition. 
Christens son, Arborelius and Lilja (1981) argue that MDI use is as effective as all other 
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delivery systems and shows no significant difference even when compared to the 
nebulizer delivery system. Findings by Pedersen and Bundgaard (1983) support the 
notion that spacers aren't more effective over MDI's by showing that the spacer was no 
more efficacious in the delivery of aerosol medication with asthmatics who have proper 
inhalation coordination when using the MDI. Current research is centered upon static 
charge surrounding the spacer devices and how this can disrupt the drug delivery 
(Wilhaber, Devadason, Eber, Hayden, Everard, Summers & LeSouef, 1996). Such 
research has lead to further study on how the multiple actuation process of releasing the 
salbutamol into the spacer disrupts medication flow to the lungs (Wildahaber, 
Devadason, Hayden, James, Dufty, Fox, Summers & LeSouef, 1996). No research has 
been done on the effects the delivery systems have on EIA and post-exercise lung 
function. A question that this study endeavours to answer. 
2.3 Summary 
With the majority of past asthma study concentrating on drug development and 
effectiveness in preventing asthma, research on the topic of delivery systems of these 
drugs has been neglected. Causation of an asthmatic episode has been defined and 
described within the body of this proposal, however, the lack of discussion on the 
spacer and MDI is representative of the deficiency in published research in the area of 
study in question. To this authors knowledge, spacers and MDI's have never been 





Thirteen (10 female and 3 male, mean age = 24 yrs SD = 7.44yrs) healthy 
asthmatics were recruited from the Edith Cowan University Joondalup and T AFE student 
populations. Subjects were considered active, based on their participation in sport over the 
past 3 months (all participated in some form of exercise at least 3 times per week for no less 
than 1 hour per session). All subjects consistently experienced EIA and were prescribed 
Ventolin™ by their physician for preventative measures against the condition. A general 
medical information questionnaire and signed consent was completed prior to any testing 
(Appendix B). All subjects had the procedures explained to them and were provided with 
information sheets that addressed consistency procedures and research procedures to ensure 
standardised testing and standardised preparation was maintained. (Appendix B) Medical 
clearance was compulsory and obtained for each subject either through their own general 
practitioner or the Edith Cowan campus doctor. 
The research was approved by the Human Rights Committee of Edith Cowan University. 
3.2 Study Design 
This study employed a single-dose, single blind, placebo controlled cross-over 
study. There were three laboratory treatment sessions for each subject. No two treatments 
were conducted on the same day with a minimum of 2 days and a maximum of 5 days 
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between tests. Five specific lung function measures were recorded post-exercise to 
investigate the efficacy of two different delivery systems of aerosol salbutamol. 
3.3 Reliability Study 
To ensure experimenter familiarity with the autospirometer and to establish 
reliability, a pilot study was undertaken to determine the consistency of the Minato 
Autospiral spirometer. Thirty non-asthmatic subjects performed lung function tests on 2 
occasions over 2 weeks. Reliability was determined using an interassay test-retest protocol 
and the results examined by a Pearson Product Moment correlation and by application of 
the Student t-test for related groups. The pulmonary function variables examined for the 
determination of reliability were those measured in the major research project. 
3.4 Instruments and Materials 
Track master Tm400 treadmill 
Polar edge heart rate monitor 
Glaxo Wellcome Volumatic™ Spacer device 
Glaxo W ellcome Metered dose inhaler 
Ventolin™ (3 canisters) 
Placebo (3 canisters) 
Auto spirometer 'Minato AUTOSPIRAL PAL'. 
Mouth pieces 
Borg scale of Perceived Breathlessness 
Nose clip 
Toshiba Pentium Laptop computer 
PalSoft software (Switzerland) 
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3.5 Research Protocols 
Each subject completed 3 testing sessions involving a standard asthma exercise challenge 
following pre-exercise inhalation of either: 
1) salbutamol via MDI and placebo via spacer 
2) placebo via MDI and salbutamol via a spacer 
3) placebo via MDI and placebo via spacer. 
The severity of EIA was assessed from FEV 1 and other selected lung function 
measurements obtained pre and post-exercise. Pre-medication measures were used as a 
baseline figure with which all subsequent lung function results were compared. Lung 
function tests took place at pre-medication, 5 minutes post-medication, pre-exercise and at 
7 given post-exercise time periods: Immediately post exercise and at 3, 5, 7, 10, 20 and 30 
minutes. See Figure 3.1. 
Post-exercise Measures 
• • • • • 
I 
0 5 13 3 .5 
Time (minutes) 
Lung function test: • 
Graded exercise: -
Plateau foI" 4 mins. 
• • • • 
1 10 20 30 
Figure 3.1. Time display for graded running protocol with Lung Function test times shown. 
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In order to assess subjects perceived level of breathlessness, the Borg Scale of 
Perceived Breathlessness (Appendix D) was used and scores recorded every minute during 
the 8-minute exercise challenge and whenever post-exercise lung function measures were 
conducted. The 8-minute exercise challenge involved a multi-stage-continuous treadmill 
run with gradual increases in severity over the first 3 to 4 minutes, achieved by adjusting 
speed and grade. The increases in workload were manipulated so that the subject was 
exercising at 75-85% predicted HRmax by the 4th minute thus ensuring at least 4 minutes of 
exercise at this level. All testing was carried out in a laboratory where the environment 
maintained at l 9°celcius (range = 17°-21 °) with humidity remaining relatively consistent at 
55% (range= 47%-63% ). 
Prior to testing, all environmental measures were recorded (temperature, barometric 
pressure and humidity) for calibration purposes. All lung function measures were corrected 
to body temperature, ambient atmospheric pressure and saturated with water vapour 
(BTPS). 
3.5.1 Experimental Testing Sessions 
Each subject attended three exercise testing sessions in the physiology laboratory at 
Edith Cowan University, Joondalup. The order of pre-exercise treatments was randomly 
assigned to each of the three experimental testing sessions with single blind administration 
of the salbutamol and placebo. The placebo, salbutamol, spacers and metered dose inhalers 
were supplied by the Human Movement department at The University of Western 
Australia. Both the placebo and salbutamol canisters were identical except for code 
numbers (see Figure 3.2). The placebo consisted of aerosol propellant only. 
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Figure 3.2 Metered dose inhaler with Ventolin cannister (2) and placebo cannister (1). 
On arrival for each testing session, the subject' s body mass and height were 
determined and entered into the Autospiral data bank. The subject was then fitted with a 
Polar Edge heart rate monitor and instructed to sit alongside the spirometer. Once seated, 
pre-treatment lung function measures were recorded involving the best of two trials 
utilising the FVC manoeuvre, with nose clip in place to prevent air escaping through the 
nasal passages (Figure 3.3). All data were recorded by the Autospiral autospirometer and 
immediately downloaded to an adjoining Toshiba laptop computer. 
Figure 3.3 FVC manoeuvre employed for lung function testing with Autospirometer and attached 
Laptop computer. Subject seated and nose-clip attached . 
. . 
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Following a revision of spacer and MDI use techniques, the subject self-administered the 
allocated treatment (Figures 3.4 & 3.5). Placebo and/or salbutamol were administered via 
the MDI and spacer as two actuations one minute apart according to the instructions in 
Appendix C. Each actuation provided 100 11g ofthe medication/placebo. 
Figure 3.4 Correct spacer assisted MDI actuation . Figure 3.5 Correct metered MDI actuation. 
All subjects were closely observed during treatment to ensure optimal technique 
was used. After 5 minutes seated rest, the pulmonary function tests were repeated. 
Immediately after the ' post-medication' scores were completed, the subject began the 
exercise challenge on the treadmill with nose clip attached (Figure 3.6). 
The initial sp~ed and grade was determined by feedback given from the subject on 
what they considered as being a 'comfortable' warm-up level. For the following 2 minutes, 
speed and grade was manipulated by the tester to attain a HR. which corresponded to the 
required test level. After the first 3-minutes of exercise, which represented a warm-up, the 
subject achieved a running pace which induced a heart rate equivalent to 75-85% predicted 
HR.max. This was maintained until a total of 8 minutes was completed. Each minute, 
reports of perceived breathlessness and heart rate were obtained. 
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Immediately ( < 30 seconds) after the cessation of exercise, the pulmonary function testing 
was performed and repeated at 3, 5, 7, 10, 20 and 30 minutes post-exercise. Borg scale 
readings and heart rate were also measured at these time intervals. At the end of the 30-
minute post exercise period, the subject's lung function results were checked to ensure 
adequate recovery(> 75% of initial value) before allowing them to leave the laboratory. If 
this level of recovery was not attained, Ventolin was administered and lung function 
monitored until the criteria was achieved. 
3.5.2 Measurement Procedures 
3.5.2.1 Total Body Mass 
Body mass was determined with the subject wearing minimal clothing, running 
shorts (male) or running shorts and lightweight singlet (female) without foot attire. 
Subjects stood erect on the centre of a Mettler electronic scale ensuring minimal movement. 
Mass was recorded to the nearest 10 grams. 
3.5.2.2 Standing Height 
Standing height was obtained using a Holtain Stadiometer. Subjects stood erect 
with heels, buttocks, posterior aspect of the thoracic region and head against the vertical 
plane of the stadiometer. Heels were slightly apart and the arms hanging in a relaxed state. 
Using a pistol grip, the subjects head was manipulated into the Frankfurt plane by applying 
slight upward pressure on the jaw and occipital bone. Height was read from the scale and 
rounded to the nearest centimetre. 
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3.5.2.3 Ambient temperature, Barometric pressure and Relative humidity 
Ambient temperature and relative humidity within the air-conditioned physiology 
laboratory was determined using an aspirated psychrometer (whirling hygrometer). This 
was carried out prior to each subject's initial pulmonary function measurement. Barometric 
pressure was determined using a mercury barometer. As the barometric scale was in mm of 
Hg and the Autospiral required this parameter to be expressed in kPa, the value, expressed 
in mmHg, was multiplied by 0.13333. The barometric pressure, ambient temperature and 
relative humidity were all used to calibrate the Minato Autospiral pal and used to correct 
lung function values to BTPS. 
3.5.2.4 Pulmonary Function Testing 
The Minato: Autospiral Pal autospirometer was used for all lung function testing. 
Each subject used a separate sterilised filter and a new cardboard mouthpiece for each 
testing session. A small amount of tape was used to guarantee a tight seal between the 
mouthpiece and the Autospiral transducer. Prior to each testing session, the Autospiral Pal 
was calibrated to the manufacturers instructions, as described in Appendix E. 
To determine the influence of two different methods of Ventolin on exercise-induced 
asthma following a standardised exercise challenge, nine separate tests were carried out 
during each of the three sessions. A flow volume test (PVC pre-test) was applied to record 
the 5 lung functions in question (PVC, FEV1, FEF50, FEF25_75 and PEFR). Subjects were 
given 2 trials at each time point with a short break of approximately 5 seconds between 
trials. During each pulmonary function test, subjects sat comfortably on a chair with feet 
flat on the ground. A nose clip was worn for all tests (Figure 3.3). Subjects were required 
to have the lips sealed around the mouthpiece, the end of which was positioned just beyond 
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the teeth. Throughout the inhalation and exhalation procedure, subjects were given verbal 
encouragement to ensure an optimal result was achieved for every FVC manoeuvre. 
3.5.2.5 Rating of Perceived Breathlessness 
Rating of Perceived Breathlessness was recorded during the last 10 seconds of each 
test using the Borg category scale (breathlessness) with ratio properties (Appendix D) The 
Borg scale chart was placed at eye level in front of the treadmill. Indication of the rate of 
breathlessness was obtained verbally or by physical sign. 
3.5.3 Data Analysis 
Heart rate, treadmill protocols and lung function measures were recorded on data 
collection forms for the 3 visits (Appendix F). All post-medication; pre-exercise and post-
exercise scores from each test session for each subject were expressed as a percentage of 
the pre-medication score obtained at that session. 
EIA was determined achieved if maximum decrement on FEV1 was greater than 10%. The 
significance of the differences between the means were tested over the three different 
treatments and seven post-exercise time periods by application of a treatment x treatment x 
subjects design analysis of variance (T x T x S ANOV A). Using this test, F ratios were 
computed for three factors. These being; treatment, time and the treatment/time interaction. 
When significant main effects were obtained (p < 0.05) for treatment only, the post hoc all 
possible simple contrasts function was implemented to locate the significant simple main 















applied to each of the 7 time periods to locate where significant F ratios existed between 
treatments. The post hoc; all possible simple contrasts method was used to isolate the 
simple main effects between the treatments for each time period that showed a significant F 
ratio (p < 0.05). When the treatment/time interaction showed a significant F ratio, 
regardless of the other two factors, the significant F values were investigated by examining 
the simple effect of treatment at each level of time using a related samples t-tests. When 
the time factor demonstrated a significant F ratio, the mean value at each time period was 
tested using related samples t-tests. This test ignored differences shown across treatments 
and concerned the mean value of all three tests at each time, it was therefore considered not 
central to the research questions and thus reported rarely within the results section. 
Maximum decrement and bronchial }ability statistical analysis was completed by a oneway 
repeated measures ANOV A. Where significant F ratios were obtained, thus indicating a 
significant difference between tests, a post hoc test of within subjects contrasts was applied 
to distinguish which tests differed to the p < 0.05. Raw data for all tests are presented in 
Appendix A. 
3.6 Limitations 
1. Subjects were unpaid volunteers whose level of motivation during tests could be 
expected to vary. Although subjects were continuously encouraged, motivation could 
not be controlled. 
2. Variation in severity of airways disease and responsiveness to the exercise challenge. 
3. It is uncertain how each subject's level of fitness will influence the results. 
4. The equipment required to measure effort independent airways resistance was 
unavailable. 
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5. Availability of a climatic chamber was also a limiting factor as conditions in the 
laboratory are controlled for temperature only and not humidity. This may hinder 
asthmogenic effect of the exercise challenge. 
5. Although subjects were instructed to abstain from medication prior to testing (see 
Appendix G), the pro-longed effects of some drugs on bronchoconstriction are unknown 
and may prevent some asthma symptoms. 
3.7 Delimitations 
1. Subjects were 18-40 years of age with a history of EIA. 
2. All were prescribed Ventolin for their condition by their physician. 
3. Sedentary subjects were excluded 







Repeated measures of lung function tests used in this study proved reliable 
based on the high correlation coefficient and coefficients of variation for repeated 
measures (Table 4.1). The application of a paired samples t-test confirmed that there 
were no significant differences between the two test sessions (See Table 4.2). Raw data 
for the reliability study is presented in Appendix H. The FVC and FEV1 variables 
proved most reliable (< 5% Coefficient of Variation), with the MEF50 and PEFR 
showing the least reliable statistics. 
Table 4.1 Correlation, Method error and the coefficient of variation for FVC, FEY i.. 
FEF50, FEF75_75 and PEFR values obtained from reliability study. (n=30) 
Pearsons product Coefficient of Method Error 
moment Correlation variation (V) 
FEV1 .961 a 4.14 0.165 
FVC .957 a 4.21 0.200 
FEF25-75 .923 a 7.49 0.312 
PEFR .857 a 7.51 0.690 
MEFso .887 a 9.62 0.466 
• indicates significant correlation p < 0.01. 
Table 4.2. Mean. Standard deviation and significant differences of test - retest 
pulmonary function scores using the Minato Autospirometer. (n=30) 
Variable 
Test-1 Test-2 
mean (± SD) mean (± SD) t-value p value 
FEV1 (L) 3.98 (± 0.79) 4.00 (± 0.84) -0.602 0.552 
FVC (L) 4.71 (± 0.87) 4.74 (± 0.95) -0.635 0.530 
FEF25-75 (L.min-1) 4.15(±1.11) 4.18(±1.13) -0.510 0.614 
PEFR L.min-1) 9.19 (± 1.86) 9.16 (± 1.76) 0.133 0.895 






Although fifteen subjects were recruited, only thirteen subjects ( 10 female and 3 
male) completed the study. After the three 8-minute exercise challenges, only 7 
subjects displayed falls in FEV 1 consistent with the criteria for an EIA episode (ie > 
10% decrease in post-exercise FEV1) even though EIA had been confirmed with all 
subjects General Practitioners. Subsequent data analysis was limited to results obtained 
from within this group (Subject characteristics are shown in Table 4.3). 















To allow for variation in age, sex and physique when comparing the results of each 
ventilatory function test, all values for each subject were expressed as a percentage of 
the pre-medication, pre-exercise score where appropriate. 
4.3 Pre-Treatment Baseline Pulmonary Function 
When the scores obtained prior to treatment (pre-treatment scores) for each of 
the three sessions were analysed using a repeated measures ANOV A, the F ratio was 
not significant for between tests comparisons except for the PEFR pulmonary variable 
where a simple post hoc contrast demonstrated a simple main effects significant F value 
between the mean MDI value and the mean placebo value (F = 8.123, p = 0.029). Table 
4.4 shows the mean baseline pulmonary values for each of the five variables. 
Temperature and relative humidity did not vary significantly between testing sessions. 
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Table 4.4. Baseline pulmonary values pre-medication. (n = 7) 
Pulmonary function 
MDI Spacer Placebo 
variable 
mean(± SD) mean(± SD) mean(± SD) 
FVC (L) 4.47 (± 0.95) 4.36 (± 0.94) 4.16 (±0.76) 
FEV 1 (L) 3.31 (± 0.85) 3.06 (± 0.88) 2.92 (± 0.71) 
FEF 25-75 (L.min-1) 2.82 (± 1.33) 2.48 (± 1.27) 2.42 (± 1.18) 
PEFR .(L.min-1) 7.73 (± 2.70)# 6.15 (± 1.90) 5.64 (±1.53)# 
MEF 50 (L.min-1) 3.27 (± 1.50) 2.82 (± 1.54) 2.73 (± 1.38) 
# indicates significant differences between MDI and Placebo to the p < 0.05 level. 
4.4 Pulmonary Function Variable Results 
4.4.1 FEV1 
4.4.1.1 Pulmonary Changes post-exercise. 
The mean FEV I changes for the 3 different treatment groups (Figure 4.1 ), 
demonstrated that only the spacer treatment had a positive effect on FEV I post-exercise 
scores. Table 4.5 shows the normalised mean post-exercise values for each pulmonary 
measure. The spacer achieved a mean change in post-exercise FEV I of 11.7%. (± 24.8) 
whereas the MDI and placebo scores achieved -1.7% (± 10.2) and -13.3% (± 16.5) 
respectively. It is apparent that, although the MDI treatment had little effect in 
increasing FEV I function post-exercise, it did prevent the EIA that was evident in the 
placebo scores. A treatment by treatment by subjects ANOV A demonstrated a 
significant F ratio between the test/time interaction (F = 2.514, p = 0.008), which was 
isolated between the mean spacer treatment score and the mean placebo treatment score 
at the ]1h post-exercise minute only (p = 0.045). No significant differences between 
placebo and Ventolin via MDI or between Ventolin via spacer or MDI were found for 
any time period. 
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Figure 4.1. Mean and Standard Error for FEV1 Changes Expressed as a Percentage of 
the Pre-treatment value. (n = 7). 
"' =indicates significant difference between Spacer and Placebo scores (p < 0.05) 
- Red line represents the % range in normal values ex-pressed as a standard error as found for non-
asthmatics during the reliability study. 
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Figure 4 .2. Mean and Standard Error for PEFR Changes Expressed as a Percentage of 
the Pre-treatment value. (n = 7). 
- Red line represents the % range in normal values expressed as a standard error as found for non-
asthmatics during the reliability study . 
. · 
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Table 4.5. Percentage Change in Post-Exercise Lung Function Mean and Standard 
Deviation (n=7). 
Pulmonary function MDI Spacer Placebo 
variable mean(± SD) mean(± SD) mean(± SD) 
FVC 
99.30 105.80 90.03 
(± 5.75) (± 13.99) (± 12.54) 
FEV1 
98.26 111.69 86.66 
(± 10.26) (± 24.80) (± 16.55) 
FEF2s-1s 
100.18 124.47* 82.61* 
(± 27.19) (± 39.88) (± 20.31) 
PEFR 
88.21 110.81 93.06 
(± 9.78) (± 33.76) (± 28.21) 
MEFso 
101.19 130.88* 83.79* 
(± 30.22) (± 44.48) (± 21.76) 
* indicates significance between the spacer and placebo scores to the p < 0.05 level. 
4.4.1.2 Maximum Decrement and Bronchial Lability 
Mean results for maximum decrement and bronchial }ability are presented in 
Figures 4.6 and 4.7. Comparison of FEV1 scores over the 3 treatments indicated that 
the greatest drop occurred after the placebo test (mean = 28.6% ± 20.7). The MDI 
recorded a decrease of 12.2% (± 11.2) and the spacer displayed a mean maximum 
decrement of 9.6% (± 11.7). Note that no significant differences between tests were 
found. (F = 2.876, p = 0.095) Lability scores between the 3 treatments demonstrated 
that MDI resulted in less }ability than the spacer, with the placebo treatment generating 
the greatest score (Figure 4.6), again no significant differences were obtained between 
the bronchial }ability scores for FEV1 post-exercise (F = 3.641, p = 0.058). Raw data for 
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Figure 4.6 Mean and Standard Error for Bronchial Lability Scores obtained for the 
three treatments. 
*=indicates significant difference between MDI and Placebo scores (p < 0 .05) 
4.4.2PEFR 
4.4.2.1 Pulmonary Changes post-exercise. 
The mean PEFRchanges after the 3 different treatments are shown in figure 4.2. 
The placebo and spacer treatment scores showed a tendency to increase immediately 
post-treatment, however Ventolin via MDI showed a slight decrease at this time and did 
not show any improvement until after the 20u1 minute. All three treatments showed a 
declining trend in PEFR immediately post-exercise with improvements only apparent 
after the 7tb. minute post-exercise. No significant F ratios were obtained between the 
tests, however, a significant increase in all PEFR scores occurred between the 10111 and 
20th minute (p = 0 < 0.01). Note that this significant difference refers to the difference 
recorded between the 1 otb. and 20tb. minutes and not in comparison to the pre-treatment 
values. The Spacer treatment maintained PEFR function above the pre-treatment value 
throughout _the testing procedures with a mean post-exercise increase of +10.8% (± 
•' 
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33. 7). MDI scores had a tendency to remain below the pre-treatment value through out 
the test with a mean post-exercise fall of 11.8% (± 9.8) being recorded. Placebo scores 
displayed a smaller fall than the MDI scores with a mean post-exercise value of -6.9% 
(± 28.2). No significant F ratios were obtained for any of these differences. 
4.4.2.2 Maximum Decrement and_ Bronchial Lability 
A oneway ANOV A with repeated measures indicated that bronchial lability 
scores between the three treatments showed a significant F value of 4.151 (p = 0.043) 
for PEFR. The placebo test recorded the greatest lability score of 53.1% (± 18. 7) with 
the MDI recording the lowest lability of 28.2% (± 12.6). Significance was achieved 
between these two scores only (p = 0.037). Spacer bronchial lability scores were not 
significantly different from the MDI results. No significant differences in the maximum 
decrement scores occurred between the 3 treatments. (see Figure 4.7). 
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Figure 4.7 Mean and Standard Error for Maximum Decrement Scores obtained for the 
three treatments. 
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Figure 4.3. Mean and Standard Error for FVC Changes Expressed as a Percentage of 
the Pre-treatment value. (n = 7). 
*=indicates significant difference between Spacer and Placebo scores (p < 0.05) 
- Red line represents the % range in nonnal values expressed as a standard error as found for non-asthmatics during 
tl1e reliability study. 
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Figure 4.4. Mean and Standard Error for FEF25_75 Changes Expressed as a Percentage of 
the Pre-treatment value. (n = 7). 
*=indicates significant difference between Spacer and Placebo scores (p < 0.05) 
- Red line represents the % range in normal values ehrpressed as a standard error as found for non-
asthmatics during the reliability study 
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4.4.3 FVC 
4.4.3.1 Pulmonary Changes post-exercise. 
The mean FVC changes after the 3 different treatments shown in Figure 4.3, 
show similar trends to that reported in section 4.4.1.1. The spacer treatment was the 
only test that maintained mean post-exercise lung function scores above the pre-
treatment value ( + 105.8% ± 13.9). Although the MDI and the placebo had negative 
mean post-exercise scores for FVC (see Table 4.5), the MDI prevented the FVC from 
falling below the pre-treatment value by more than -2.57% (± 7.99). A significant F 
ratio was obtained for the test/time interaction and the analysis of simple main effects 
showed that the only significant difference occurred at the ih post-exercise test time 
between the placebo treatment and spacer treatment scores. (p = 0.048). No other 
significant differences were found between tests. 
4.4.3.2 Maximum Decrement and Bronchial Lability. 
A significant difference within the sample data was found for bronchial }ability 
only (F = 4.145, p = 0.043), with the placebo }ability score 24.4% (± 17.9) being 
significantly greater than the MDI score 10.6% (± 6.1) (p < 0.05). Maximum decrement 
scores were 20.7% (± 19.9) for the placebo treatment and only 6.9% (± 7.6) and 5.6% 
(± 6.7) for the MDI and spacer tests respectively (difference N.S). 
4.4.4 FEF2s-7s 
4.4.4.1 Pulmonary Changes post-exercise. 
The mean FEF25_75 changes after the 3 different treatments (Figure 4.4), show 
substantially larger differences in the three treatment scores. This is to be expected 




All three treatments show positive trend scores at post-treatment and immediately post-
exercise with regard to their pre-treatment values. The spacer treatment recorded the 
fastest rate at this point with the score reaching +45.3% (± 65.8) above the pre-
treatment value. Declines in all three treatments between O and 3 minutes occurred, 
which leveled off until the 10th minute post-exercise. Note that only the spacers mean 
scores were above the 100% value between these times (Figure 4.4). The MDI recorded 
a mean post-exercise FEF25_75 score of 100.2% (± 27.2) implying that it prevented 
bronchoconstriction even though there was no significant F ratio between it and the 
placebo scores. (See Table 4.5 for the mean post-exercise pulmonary function scores). 
Significant F ratios were obtained between tests (F = 3.992, p = 0.047). Analysis of the 
simple main effects demonstrated significant differences between the mean placebo 
scores and mean spacer scores only at the 3rd, 7th, 10th and 20th time intervals (p < 0.05). 
4.4.4.2 Maximum Decrement and Bronchial Lability 
Decrement scores for FEF25_75 shows that the placebo had the greatest maximum 
mean decrement between all three tests; 38.48% (± 23.22), with the MDI and the spacer 
recording 19.6% (± 20.2) and 11.8% (± 16.8) respectively. No significant F ratios were 
found for any of the maximum decrements or the }ability scores recorded for FEF25_75 (F 
= 3.387, p = 0.068 & F = 0.546, p = 0.593 respectively). The highest }ability score was 








4.4.5.1 Pulmonary Changes post-exercise. 
The mean MEFso changes after the 3 different treatments are shown in Figure 
4.5. The trend demonstrated is very similar to that recorded for FEF25_75 due to the fact 
that MEFso is a measurement taken within the middle of the for FEF25_75 score. As with 
the results in section 4.4.4.1, all three treatments had an upward trend until immediately 
post-exercise whereafter they all declined and leveled off at the 3rd minute post-
exercise. The spacer treatment for MEF50 peaked at the O minute post-exercise interval 
with an increase of 52.1 % (± 75.3) compared to the pre-treatment value. From the 3rd to 
10th minute, this value stayed within a range of +20% to +26%. The MDI had a mean 
post-exercise value of 101.2% (± 30.2), however, as found within section 4.4.4.1, the 
mean score was below the 100% data line from the 3rd to 10th post-exercise time 
intervals. The placebo treatment recorded a mean post-exercise fall of -16.2% (± 21.8) 
and was found to be significantly different from the spacer treatment scores at the 3rd, 
7th, 10th and 20th time intervals post-exercise (p < 0.05). No significant differences 
between placebo and Ventolin via MDI or between Ventolin via spacer or MDI were 
found for any time period. 
4.4.5.2 Maximum Decrement and Bronchial Lability 
Maximum decrement and bronchial lability scores for MEFso over the 3 
treatments demonstrated no significant differences between tests. (F = 3.098, p = 0.082 
& F = 0.846, p = 0.453 respectively). The trends shown within the other pulmonary 
variables were repeated by the MEF5o scores with the placebo showing the greatest 
bronchial !ability and maximum mean decrement. The MDI had a greater 
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decrement over the spacer treatment but showed a lower mean lability. These results 
are presented in Figures 4.6 and 4.7. 
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Figure 4.5. Mean and Standard Error for MEF50 Changes Expressed as a Percentage of 
the Pre-treatment value. (n = 7). 
*=indicates significant difference between Spacer and Placebo scores (p < 0.05) 
~ Red line represents the %range in normal values e"-pressed as a standard error as found for non-
asthmatics during the reliability study 
4.5 Heart Rate and Rate of Perceived Breathlessness {RPB). 
The recovery and exercise heart rate and RPB scores are shown in table 4.6. 
The mean heart rates recorded during exercise and recovery were within 3 bpm for each 
test. Mean exercise and recovery RPB scores also varied only slightly, with a range of 
0.5 and 0.4 for exercise and recovery respectively. Using a repeated measures 
ANOV A, there were no significant differences between the three treatment values for 
exercise and post-exercise recovery heart rates and RBP scores . 
. · 
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Table 4.6 Mean HR and RPB results for the 3 test periods 
MDI Spacer Placebo 
mean(± SD) mean(± SD) mean(± SD) 
Heart rate RPB Heart rate RPB Heart rate RPB 
J 




104 2.4 107 2.3 105 2.7 









The purpose of this study was to compare the efficacy of a spacer device to that of 
the metered dose inhaler in the delivery of the aerosol medication, salbutamol for the 
prevention of exercise-induced asthma. Although the spacer assisted delivery 
demonstrated no significant benefit over the MDI method, the data obtained raises 
questions over the circumstances under which testing occurred. Only 7 of the 13 
subjects displayed falls in FEV 1 sufficient to be classified as exercise-induced asthma, 
even after proven steps were taken to stimulate such responses. Subjects stated that 
during exercise, they experienced an asthma attack on a regular basis. Furthermore, all 
medical practitioners confirmed each of the subjects' asthmatic condition. All subjects 
were non-smokers and healthy; so why didn't 6 of the 13 subjects show a fall in FEV 1 
over the three tests, large enough to be classified as EIA? 
Chapter 3 explained the steps taken to provoke an EIA episode. Nasal breathing 
was employed to enhance RWL and RHL and subjects were instructed to refrain from 
medication according to the guidelines in Appendix G. Laboratory ambient temperature 
remained constant however a relatively large variation in the relative humidity was 
recorded. Henriksen, Dahl and Lundqvist ( 1981) demonstrated that humid air can 
decrease the bronchospastic response in asthmatic subjects, with the range of relative 
humidity recorded during this study (47% to 63%), causing up to 30% fewer cases of 
EIA than in relative humidities of 15% to 20%. Secondly, as EIA is defined as a fall in 
FEV1 of more than 10%, attainment of EIA may have been hindered by the relatively 
large bronchial lability scores implying that some bronchoconstriction was evident in 
subjects prior to testing. This suggestion is supported by the normative pulmonary 
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function values generated by the Minato Autospirometer suggesting that on each visit, 
subjects obtained mean pre-treatment FEV1 scores that were only 85% their normal 
expected value. 
One may question the reliability of such norms, however the Minato Autospirometer 
processes the norm calculation on previously calculated norms based on age, sex, height 
and weight collected from 25 year old Caucasians. All subjects in this study were 
Caucasian with a mean age of 24.07. 
An asthmatic patient suffering from no bronchoconstriction will often achieve 
near normal lung function results. If it was the case that bronchoconstriction was 
evident in a number of subjects prior to testing, then an explanation for this must be 
addressed. Asthma can be caused by allergies, exercise or certain climatic scenarios. 
The testing was undertaken in the middle of spring thus suggesting environmental 
conditions may have caused the pre-exercise constriction. According to Kaliner, 
Eggleston and Mathews ( 1987), the most important technique for preventing an 
asthmatic episode is avoidance of airborne allergens. Avoidance of such allergens was 
difficult at the laboratory used for testing as it's location within a pine plantation may 
have exposed subjects to abnormally high airborne pollen which is a known 
asthmogenic allergen. (Morton, in Bloomfield, Fricker & Fitch, 1992, p.537). The 
pollen count for Perth (presented in Appendix J) shows that the testing period for this 
study coincided with the highest pollen counts taken for spring. Also note that the pine 
pollen count represented a large percentage of the total pollen count thus supporting the 
suggestion that the location of the laboratory was perhaps contributory to the significant 
bronchoconstriction evident in some subjects. This problem could easily be avoided if 
testing occurred in the late summer months therefore ensuring lower pollen counts and 









Due to the nature of this study, time and equipment constraints prevented the use of 
controlled air conditions for testing. Hahn ( 1984 ), Papalia ( 1991) and Rossi ( 1995) all 
found that nearly 100% of subjects achieved post-exercise EIA with the use of a 
climatic chamber which maintained a low relative humidity and regular temperature. 
To ascertain whether or not the data obtained in this study presents a true indication of 
spacer efficacy, the research should be replicated with the use of a climatic chamber to 
ensure a higher level of consistency and asthmogenic conditions. 
It is also a possibility that the occurrence of EIA may have been reduced if subjects 
demonstrated a relaxed approach to the instructions concerning short and long-term 
preventative medications. This fact is unproven, however future study should 
encompass the importance of following the medication guidelines to optimise EIA 
development in subjects. 
Due to time constraints, it was not possible to pre-determine, using a 'familiarisation' 
session, whether or not the subjects had a tendency to demonstrate EIA under the 
provided laboratory conditions. Again, this extra visit would have exempted several 
subjects from the study who were not prone to EIA under the given circumstances. 
Eggleston (1979) suggests that such familiarisation sessions can improve the 
reproducibility of the airways response to exercise. Through this kind of subject 
selection process, a sample that was likely to experience EIA would have been ensured. 
Variation between tests could also have negatively influenced the achievement of EIA. 
According to Silverman and Anderson ( 1972), tests for EIA that were performed on 
separate days within one week generated average coefficients of variation in pulmonary 
function of 21 %. They state that this was due to changes in the sensitivity of the 
asthmatic to exercise rather than experimental error. Fortunately, the airways response 







sensitivity to exercise. This fact coupled with the finding in this study that significant 
variation occurred within the subject's scores at the baseline, pre-treatment level, 
presents a hindrance to the reproducibility of similar testing conditions between tests. 
Sly (1970) and Eggleston and Guerrant (1976) argue that such changes in an asthmatics 
resting airways calibre influences EIA testing results minimally thus ruling this concern 
unwarranted. By implementing an incremental exercise challenge, Godfrey (1974, 
p.34) believes that more variable results are obtained than in tests that maintain a single 
work rate throughout the entire tests. This study employed an incremental protocol 
which, even though it was replicated across treatments, may have caused some variation 
in results. 
Data obtained over the three treatments illustrate that the spacer device resulted 
in significantly less airway obstruction following exercise compared to the post-exercise 
results obtained following placebo treatment. The MDI presented no significant 
differences when compared to both the spacer and placebo scores. FEV 1 will be 
discussed in depth as it is the benchmark pulmonary variable for the measurement and 
diagnosis of EIA. 
5.1 FEV1 
The occurrence of EIA between treatments was limited due to only 7 subjects 
demonstrating adequate falls in FEV1. The spacer treatment prevented 4 subjects from 
suffering EIA, with the placebo and MDI preventing 3 subjects post-exercise. The 
severity of EIA may have been greater than recorded if }ability scores weren't as 
elevated as they were. Jones, Bus ton and Wharton ( 1962) recorded similar }ability 
scores as this study, yet these were not accounted for and their conclusions made 
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concerning the effect exercise has on FEV1 have been repeatedly disputed (Morton, 
Lawrence, Fitch & Hahn, 1983). From the results obtained in this study, the efficacy of 
the spacer to improve post-exercise FEV 1 values obtained under EIA conditions proved 
not significantly superior to the MDI treatment when administering salbutamol. The 
recorded lack of contrariety between the two devices in question may be due to the 
capable and coordinated approach the majority of subjects possessed with regard to 
MDI use. It is apparent that the subjects within this sample were experienced MDI 
users. This was confirmed by all subjects carrying their MDI's on their person at all 
times. With a mean age of 24yrs, the results obtained from this study are comparable to 
similar studies by Gomm, Keaney, Winsey and Stretton (1980) who, using a cognate 
sample, found no statistical significance between the MDI and the aerochamber when 
measuring post-treatment FEV 1, FVC and PEFR. Adult asthmatics were also used in 
studies performed by Newman et al (1984); Comis, Valletta, Sette, Andreoli and Boner 
(1993) and Dolovich, Eng, Ruffin, Corr and Newhouse (1983). These studies all 
concluded that the application of a spacer device compared to an MDI provides no 
significant improvement in FEV 1 or drug deposition within the airways. 
Based on the mean change in FEV1, the spacer prevented EIA to a greater extent 
than what the MDI achieved. Although the difference between the treatment devices 
did not prove statistically significant, in the case of elite athletes competing in highly 
competitive sports, the smallest of advantages can improve placing's or even mean the 
difference between a win and a loss. Findings by Newman, Moren, Pavia, Little and 
Clarke (1981), and Newman, Clarke, Talaee and Clarke (1989), argue in favour of the 
spacer over the MDI when being used by mature asthmatics due to a significantly 
greater amount of aerosol medication reaching the lungs with significantly lower 
stomach and oropharyngeal deposition. The opposite has also been proven by 
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Bloomfield and Crompton (1979), who demonstrated with accustomed asthmatics that 
the MDI has the capability to deliver a greater amount of drug when correct actuation is 
achieved. Without the ability to radiolabel the drug, it is impossible to determine which 
of these two theories can be applied to the sample in the current study. However, from 
the mean values obtained, it could be concluded that the spacer did deliver a greater 
amount of drug, without a significant difference in lung function variables between it 
and the MDI scores being achieved. Given the fact that all subjects in the this who 
encountered EIA, were long-term asthmatics with good MDI actuation technique, may 
explain why no significant differences between the 2 devices was recorded. In this 
context, it would be interesting to compare these findings with a group of asthmatic 
subjects having poor inhalation technique. It is conceivable that for young asthmatics, 
the spacer is the best delivery method for aerosol medication. This is maintained by 
Rivlin et al (1984 ), who showed that the spacer device can increase FEV 1 from baseline 
scores by up to 36% in asthmatic children, almost double that of the MDI. Further 
research into this hand lung 'discoordination' could provide asthmatics with the 
knowledge of when to adopt the MDI without the spacer device. Even though this 
study presented evidence that the spacer provides no real improvement over the MDI in 
mature asthmatics, many elite sporting teams still utilise the spacer to administer quick 
medication to breathless athletes who may be unable to effectively actuate an MDI 
without the aid of a spacer. This also presents an opportunity for further research into 
the effect that physical activity induced breathlessness has on the efficacy of the 
delivery of an aerosol medication via the MDI to proven coordinated MDI users. 
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5.2 PEFR 
PEFR is a measure of the velocity or rate at which air can be forcefully exhaled 
from the lungs. It is particularly useful in measuring EIA due to the difficulty in 
exhaling demonstrated during bronchoconstriction. This difficulty is directly linked to 
the degree of bronchoconstriction, therefore the slower the PEFR, the greater the 
bronchospastic response to exercise. 
The trends demonstrated in this study are consistent with prior findings involving EIA 
in that post-exercise PEFR decrement is comparable to that achieved for FEV 1 scores. 
Unfortunately, the baseline values for PEFR showed a significant difference between 
treatments. This supports the suggestion that several subjects had some form of 
bronchoconstriction prior to testing. This variation could also be due to the high 
coefficient of variation obtained for PEFR in the reliability study (Table 4.2). 
Silverman and Anderson (1972) and Eggleston and Guerrant (1976) found that when 
asthmatics perform treadmill based EIA studies on separate days within short periods, 
the average coefficient of variation for PEFR decrement can be at least 20%. From this 
finding, they concluded that, because one third of all trials produce a maximum fall in 
PEFR of either more than 1.2 times or less than 0.8 times the overall mean value, the 
airways response of asthmatic subjects to exercise is only moderately reproducible. 
PEFR is highly dependent on the subject's willingness to perform a 'maximal effort' 
exhalation consistently and correctly, which, due to psychological factors, may have 
caused some variation. This problem is not restricted to PEFR and can be applied to 
most other lung function variables. 
In answering the 2nd research question, PEFR did not differ significantly between the 
three treatments thus suggesting that there is little difference between the 2 devices in 
preventing EIA symptoms as recorded by PEFR decrement. Again, the spacer was the 
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only treatment that maintained post-exercise lung function above the pre-treatment 
value with the MDI falling lower than the placebo value for 5 of the 7 post-exercise 
time intervals. No firm conclusions can be made because of the lack of statistical 
support available from a small sample, however, the spacer would be the best option 
under situations where any slight improvement in lung function would be desirable, ie 
elite athletes. 
5.3 FVC 
The FVC is a measure of the voluntary lung capacity that an individual is able to 
exhale. In asthmatic subjects, this measure can fall by 20% in severe cases, however the 
main measure that concerns EIA is the rate at which the air can be exhaled. FVC only 
varies when swelling within the pulmonary system reduces the space within the lungs, 
thus reducing the capacity to breath or the difficulty to exhale increases the lung 
residual volume therefore reducing the amount of air moving in and out of the lungs 
(Rasmussen, Elkjaer & Juhl, 1988). Airway swelling and oedema following exercise 
only accounts for a small portion of the possible airway space therefore having only a 
slight influence on the final FVC figure. Due to the increase in residual volume caused 
by the swelling, many subjects shorten the breath cycle to puffs, which can lead to a 
smaller FVC reading. Gimeno, Berg, Sluiter and Tammeling (1972) also discovered 
that asthmatics who show declines in FVC may exasperate the condition by performing 
spirometry tests. Gimeno et al (1972) argue that with lung oedemas, the FVC 
manoeuvre can irritate the swelling thus causing premature closure of the lower airways 
during the FVC manoeuvre leading to an increase in the residual volume. This can 
produce subsequent falls in all of the lung function variables. The severity of FVC was 
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minimal in this study and generated similar scores for the spacer and MDI. Even though 
the placebo fell close to 15% post-exercise, the only significant F value was obtained at 
the ih minute between it and the spacer treatment. As there was no significant 
differences noted between the MDI and spacer scores, it must be concluded that there 
was no added benefit in using the spacer over the MDI for the prevention of PVC 
decrement within the context of EIA. 
The relatively blunted response PVC had to exercise in this study, particularly following 
the spacer treatment can been attributed to an increase in pulmonary blood flow, thus 
increasing intra-thoracic blood volume and pressure that corresponds with a 
proportional decrease in the available gas volume. (Fox & Matthews, 1981, p.244 ). 
Buono, Wilmore and Roby (1983) state that PVC is relatively insensitive to increases in 
intra-thoracic blood volume thus maintaining a relatively undisturbed residual volume 
in the lung. The scenarios presented by Rasmussen et al (1988) show residual volume 
only increasing in severe asthmatic episodes, of which none were recorded in this study. 
5.4 MEFso and FEFzs-75.:. 
MEF50 and FEF25_75 represent the rate of airflow during a PVC manoeuvre at 
specific times. MEF50 represents the rate after half the PVC manoeuvre is completed 
and FEF25_75 represents the rate recorded during the middle half of the PVC manoeuvre. 
These measures of pulmonary function are therefore good indicators of smaller airway 
functioning. Due to the relatively large degree of bronchodilation recorded during 
exercise for these variables, proportionately well above that recorded for any other 
pulmonary variable, it can be concluded that the drug did have an effect on the smaller 








Katch (1996, p.358), adrenalin release into the bloodstream causes some 
bronchodilation within the airways post-exercise. A study by Burr, Eldridge and 
Borysiewicz (1974) and Godfrey (1975) demonstrated that PEFR and FEV1 scores can 
increase up to 25% post-exercise due to these hormonal releases in non-asthmatic 
individuals. The subjects in this study demonstrated an increase in post-exercise PEFR 
and FEV1 with the spacer treatment only, however the mean post-exercise increase was 
only -10%. This suggests bronchodilatory inhibition occurred due to EIA for all 
treatments. Although little information exists on MEF50 and FEF25_75 with regard to 
hormonal induced increases, the results demonstrate that a greater amount of drug 
reached the smaller airways during the spacer treatments due to the lower amount of 
mean decrement recorded during these tests. Again, the lack of a significant difference 
between the MDI and spacer prevents any formal conclusions concerning this. Support 
for Crompton and Bloomfields' theory concerning the benefits of MDI use over the 
spacer device was given credence by Dolovich et al (1983). The latter groups research 
found that after a five-fold reduction in aerosol medication delivery to the lungs, which 
can frequently occur with MDI use, similar lung function results are achievable (as 
recorded by MEFso and FEF2s-7s), if the medication reaches the lower respiratory tract. 
This may have been the case in this study as both MEF50 and FEF25_75 scores were 
proportionately higher than the other lung function variables, thus bronchoconstriction 
may have been prevented within the smaller airways for both the MDI and spacer 
treatments. The spacer method of aerosol drug delivery is very successful at achieving 
this level of delivery and therefore maintaining post-exercise MEF50 and FEF25_75 
scores, though no more so if MDI actuation coordination is well developed in asthmatic 
subjects (Collier, Dobb & Williams, 1980). There were no significant differences 
demonstrated between MDI and spacer with regard to MEF50 and FEF25_75, therefore, in 
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answering the 4th research question, the spacer exhibited no benefit over the MDI for the 
purpose of preventing post-exercise decrement in MEF50 and FEF25_75 under EIA 
conditions. 
5 .5 RPB and Heart rate 
Heart rates were recorded in order to determine whether there was a difference 
in the cardiovascular stresses produced by the three different treatments, and to monitor 
the exercise intensity that was consequential to the degree of EIA achieved. Salbutamol 
is a specific beta-2-agonist with slight beta-1-adrenoreceptor activity (Sly, Puapan, 
Ghazanshahi and Midha 1975). Past studies have found that administration by 
inhalation minimises the quantity of salbutamol absorbed into the bloodstream through 
the alimentary canal therefore preventing beta-1-adrenoreceptor stimulation (Choo-
Kang, Simpson & Grant. 1969). As seen with the pulmonary function variables, no 
treatment caused significant differences in the post-exercise recovery periods for HR. 
This trend supports findings by Bedi, Gong and Horvath ( 1988) and McKenzie, Rhodes, 
Stirling, Wiley, Dunwoody, Filsinger, Jang and Stevens (1983), who found low blood 
salbutamol concentrations in asthmatics who showed good MDI actuation coordination, 
therefore preventing drug induced HR fluctuations. Nebulisers have a similar aerosol 
drug delivery pattern to the spacer and have been proven to increase the HR in 
asthmatics above that which the MDI can instigate (Newhouse & Dolovich 1987). This 
finding was based on earlier research that showed spacers and nebulisers contribute 
greater amounts of drug to the stomach than the MDI counterpart in subjects with 
excellent MDI coordination. As there were no differences in HR's between treatment 
groups in this study it suggests that little or no drug was swallowed during spacer 
actuation. 
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The rate of perceived breathlessness recorded in this research found the post-
exercise values were higher in the recovery for MDI treatment than the spacer but 
showed no significant differences between the two. Stark and Gambles ( 1981) used the 
RPB within a similar study and concluded that for non-asthmatics, exercise 
breathlessness was not altered by pre-exercise administration of salbutamol as did 
Freeman, Packe and Cayton (1989). Scmidt, Diamant, Bundgaard and Masden (1988), 
reported no change in sub-maximal RPB when asthmatics exercised after the inhalation 
of aerosol medication, however few studies consider the RPB post-exercise/recovery 
period. RPB recorded at these times can give a better understanding of the post-
exercise EIA stresses that are encountered by subjects that are often misunderstood by 
non-asthmatic individuals. 
CHAPTER SIX 
6.0 Summary and Conclusions. 
Research into spacer efficacy has demonstrated that for uncoordinated asthmatics, 
usually younger asthmatics, the spacer provides a significantly greater amount of 
aerosol drug to the lungs. This is achieved by the spacer's ability to reduce the aerosol 
particle speed prior to inhalation thus preventing oropharyngeal deposition which leads 
to swallowed medication (Newman et al, 1981 ). Support for the spacer is extensive 
with many researchers arguing that any level of increase in drug delivery is of 
paramount importance to overcome the effects of an asthmatic episode (Tobin et al, 
1982; Cushley, Lewis & Tatterfield, 1983). 
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More recently, the efficacy of the spacer has been questioned with Konig (1985) 
referring to them as gimmicks and Barry and O'Callaghan (1994) demonstrating the 
poor delivery patterns that a spacer can also produce. Wildahaber et al (1996) debates 
that electrostatic charge and poor valve quality on the spacer can lead to a reduction in 
drug delivery. Such conflicting views have lead to the opinion that the MDI is quite 
effective in delivering aerosol medication for coordinated asthmatics, however the 
spacer should be adopted for those asthmatics who display inhalation and actuation 
coordination difficulty. The question put before this researcher was centred on how 
applicable this recommendation is to EIA. 
On 3 separate occasions, 13 asthmatics who acted as subjects, completed a typical 
asthmogenic exercise challenge for the purpose of producing EIA that was followed by 
7 post-exercise pulmonary function tests measuring FEV1, PEFR, FVC, MEF50 and 
FEF25 _75 . The different drug delivery effects offered by the use of a spacer and MDI 
were analysed by comparing the post-exercise pulmonary values with those obtained 
pre-treatment and pre-exercise. Using a single-blind, random, double cross-over, 
placebo controlled study design for the administration of Ventolin over three tests, it 
was concluded that there was no significant benefit in using the spacer over the MDI for 
the prevention of EIA as measured by the recorded pulmonary function variables. Note 
that the subjects were all excellent MDI users thus suggesting that this conclusion can 
only be applied to asthmatics who demonstrate similar abilities in MDI actuation as 
demonstrated by this sample. 
6.1 Recommendations for further study 
In this study, several scenarios prevented 6 subjects from producing sufficient 




ability of subjects to generate asthma due to a significantly high bronchial constriction 
evident in some subjects prior to testing and the lowered asthmogenic nature of the tests 
caused by the humidity level. Future research should replicate this study in controlled 
environmental conditions to ensure the asthmogenic nature of the research. If a climatic 
chamber is unavailable, as was the case in this research, summer testing should be 
adopted to take advantage of the lower humidities, lower pollen counts and higher 
temperatures. A double blind study could be applied to reduce the chances of tester 
interference and could be achieved by having treatments prepared by an independent 
technician prior to subject and tester arrival. 
Future research could analyse the poor actuation techniques employed by breathless 
athletes during competitive scenarios such as football and other sports where 'on field' 
maintenance is permitted, and study the efficacy of the spacer and MDI under these 
conditions. Other research into the MDI design, such as employing a small lamina flow 
grid could measure the reduction in particle speed (if any) and reduce the need for 
spacer devices. Medical practitioners often promote the use of several devices in the 
pursuit of maximal asthma prevention. Newhouse ( 1997, p. 585) argues that the 
'juggling' of two or even possibly three accessory devices would be unacceptable due to 
the greater problem of confusion and therefore poor compliance such a move could 
generate. Researchers must accept that the MDI is a small and highly portable method 
of administering aerosol medication and even though the spacer presents some benefits 
in certain cases, the MDI will always be the favoured choice for asthmatics. Therefore 






Anderson, S.D, (1985). Exercise-induced asthma, The state of the art. Chest, 87(5), 
191-195. 
Anderson, S.D. (1986). EIA: New thinking and current management. The Journal of 
Respiratory Diseases. 7(11), 1-7. 
Anderson, S.D. (1986). Exercise-induced asthma. Clinical Science, 48, 1157-1175. 
Anderson, S.D.(1988). Exercise-induced asthma: stimulus, mechanisms and 
management. In Barnes, P.J., Rodgers, I.W., & Thomson, N.C. (ed). Asthma: 
Basic Mechanisms. (pp 503-522). London; Academic Press 
Anderson, S.D., Connolly, N.M., & Godfrey, S. (1971). Comparison of 
bronchoconstriction induced by cycling and running. Thorax, 26, 396. 
Anderson, S.D., & Schoeffel, R.E. (1982). Respiratory heat and water loss during 
exercise in patients with asthma. European Journal of Respiratory Diseases, 
Q1,, 472-480. 
Anderson, S.D., Schoeffel, E.R., Follet, R., Perry, C.P., Daviskas, E., & Kendall, M. 
(1982). Sensitivity to heat and water loss at rest and during exercise in 
asthmatic patients. European Journal of Respiratory Disease, 63, 459-471. 
Barry, P.W., & O'Callaghan, C. (1994). Multiple actuations of salbutamol MDI into a 
spacer device reduce the amount of drug recovered in the respirable range. 
European Respiratory Journal, 7, 17 07-17 09. 
Beaudry, H.P., Wise MB., Seely, J.E. (1967). Respiratory gas exchange at rest and 
during exercise in normal and asthmatic children. The American Review of 
Respiratory Diseases, 95:248. 
Bedi, J.F., Gong, H.J., & Horvath, S.M. (1988). Enhancement of exercise performance 
with inhaled albuterol. Canadian Journal of Sports Science, .Ll.(2), 144-145. 
Bloomfield, P., Carmichael, J., Petrie, G.R., Jewel, N.P., & Crompton, G.K. (1979). 
Comparison of salbutamol given intravenously and by intermittent positive 
pressure breathing in life threatening asthma. British Medical Journal, 1, 843-
850. 
59 
Bloomfield, P., Crompton, G.K., & Winsey, N.J.P. (1979). A tube spacer to improve 
inhalation of drugs from pressurised aerosols. British Medical Journal. ii, 1479. 
Boulet, L.P., Turcotte, H., & Tennina, S. (1989). Comparative efficacy of salbutamol, 
ipratropium, and cromoglycate in the prevention of bronchospasm induced by 
exercise and hyperosmolar changes. Journal of Allergy and Clinical 
Immunology. 83(5), 882-887. 
Bundgaard, A. (1985). Exercise and the asthmatic. Sports Medicine. 2: 254-266. 
Buono, M.J., Wilmore, J.H., & Roby, F.B. (1983). Indirect assessment of thoracic 
fluid balance following maximal exercise in man. Journal of Sports Sciences, 
l, 217-226. 
Burr, M.C., Eldridge, B.A., & Borysiewicz, L.K. (1974). Peak expiratory flow rates 
before and after exercise in school children. Archives of Disease in Childhood, 
:!2, 923-926. 
Chen, W.Y., & Horton, D.J. (1977), Heat and water loss from the airways and 
exercise-induced asthma. Respiration, 34, 305-313. 
Choo-Kang, Y.F.J., Simpson, W.T., & Grant, I.W.B. (1969). Controlled comparison 
of the bronchodilator effects of three beta-adrenergic stimulant drugs 
administered by inhalation to patients with asthma. British Medical Journal, 2, 
287-285. 
Christensson, P. Arborelius, M., & Lilja, B. (1981 ). Salbutamol inhalation in chronic 
asthma bronchiale; Doseaerosol vs nebulizer. Chest, 79, 416-419. 
Crompton, G.K. (1984). Problems patients have using pressurized aerosol inhalers. 
European Journal of Respiratory Disease, 63, (suppl 119) 101-104. 
Collier, J.S., Dobb, R.J., & Williams, I. (1980). Salbutamol aerosol causes a 
tachycardia due to inhaled rather than the swallowed fraction. British Journal 
of Clinical Pharmacology, 9, 273-274. 
Comis, A., Valletta, E.A, Sette, L., Andreoli, A., & Boner, AL. (1993). Comparison 
of Nedocromil sodium cromoglycate administered by pressurized aerosol, with 
and without a spacer device in exercise-induced asthma in children. European 
Respiratory Journal, 6(4), 523-526. 
60 
Cox, N.J.M., Van Herwaarden, C.L.A., Folgering, H., & Binkhorst, R.A. (1988). 
Exercise and training in patients with chronic obstructive lung disease. Sports 
Medicine. 6. 180-192. 
Cushley, M., Lewis, R., &Tatterfield, A. (1983). Comparisson of 3 techniques of 
inhalation on the airways response to terbutaline. Thorax, 38, 908-913. 
Deal, E.C., McFadden, E.R., & Ingram, R.H. (1979). Role of respiratory heat 
exchange in production of exercise-induced asthma. Journal of Applied 
Physiology, 46: 467-475. 
Devadason, S.G., Le Souef, P.N. (1992). Aerosol delivery systems in children. 
[unpublished paper] Available Department of paediatrics The University of 
Western Australia. 
Dolovich, M., Eng, P., Ruffin, R., Corr, D., & Newhouse, M.T. (1983). Clinical 
evaluation of a simple demand inhalation metered dose inhaler aerosol 
deli very device. Chest, 84, 36-41. 
Eggleston, P.A. (1979). A comparison of the asthmatic response to metacholine and 
exercise. J oumal of Allergy and Clinical Immunology, 63, 104-110. 
Eggleston, P.A., & Guerrant, J .L. ( 1976). A standardised method of evaluating 
exercise-induced asthma. Journal of Allergy and Clinical Immunology, 58, 
414-425. 
Eggleston, P.A., Kagey-Sobotka, A, Schleimer, RP., & Lichtenstein, L.M. (1984). 
Interaction between hyperosmolar and IgE induced histamine release from 
basophils. American review of Respiratory Disease, 130, 86-91. 
Engstrom, I, Karlberg, P & Kraepelein, S. (1960). Respiratory studies in children. 
Acta Scandanavia: Paediatrics, 49:850 
Epstein, S.W., Manning, C.P.R., Ashley, M.J., & Corey, P.N. (1979). Survey of the 
clinical use of pressurized aerosol inhalers. Canadian Medical Association 
Journal, 120, 813-816. 
Fitch, K.D., & Morton, AR. (1971 ). Specificity of Exercise in Exercise-induced 






Fox, E.L., & Mathews, D.K. (1981). The Physiological Basis of Physical Education 
and Athletics. Philadelphia: CBS College Publishing. 
Freeman, W., Packe, G.E., & Cayton, R.M. (1989). Effect of nebulised salbutamol on 
maximal exercise performance in men with mild asthma. Thorax, 44, 942-947. 
Gimeno, F., Berg, W.C., Sluiter, H.J., & Tammeling, G.J. (1972). Spirometry 
induced bronchial obstruction. American Review of Respiratory Disease, 
105, 68-74. 
Godfrey, S. (1974). Exercise Testing in Children. London: WB Saunders and Co. 
Godfrey, S. (1975). Exercise-induced asthma: clinical, physiological and therapeutic 
implications. Journal of Allergy and Clinical Immunology, 56( 1 ), 1-17. 
Godfrey, S., Silverman, M., & Anderson, S.D. (1973). Problems of interpreting 
exercise-induced asthma. Journal of Allergy and clinical Immunology, 52: 
199-203. 
Godfrey, S. Clinical variables of exercise-induced bronchospasm. In: Dempsey. J.A., 
& Reed, C.E. (1977). Muscular Exercise and the Lung. Wisconsin: 
University of Wisconsin Press. pp. 247-263. 
Gomm, S.A., Keaney, N.P., Winsey, N.J.P., & Stretton, T.B. (1980). Effect of an 
extension tube on the bronchodilator efficacy of a terbutaline delivered from a 
metered doe inhaler. Thorax, 35, 552-556. 
Gurwitz, D., Levison, H., Mindorff, C., Reilly, P.A., & Worsley, G. (1983). 
Assessment of a new device (aerochamber) for use with aerosol drugs in 
asthmatic children. Annals of Allergy, 50, 166-170. 
Gurwitz, D., Mindorff, C., Levison, H., &Reilly, P.A. (1983). Long term evaluation 
of fenoterol by two different methods of administration ( oral versus aerosol). 
Journal of Asthma, , 31-34. 
Hahn, A.G. ( 1984 ). Investigation of some possible mechanisms of exercise-induced 
asthma. Unpublished Doctoral Thesis, University of Western Australia, Perth. 
Hahn, A.G. (1985). The nature and causes of Exercise-induced asthma. The 
Australian Journal of Sciences and Medicine in Sport, 17 (2), 3-10. 
62 
..._ 
Hahn, H., Anderson, S.D., Morton, A.R., Black, J.L., & Fitch, K.D. (1984). A 
reinterpretation of the effect of temperature and water content of the inspired 
air in exercise-induced asthma. American Review of Respiratory Disease, 130, 
575-579. 
Harvey, J.E., Baldwin, C.J., Wood, K.G., Alberti, K.G., & Tattersfield, A.E. (1981). 
Airway and metabolic responsiveness to intravenous salbutamol in asthma: 
effect of regular inhaled salbutamol. Clinical Science, 60, 579-585. 
Henrisksen, J.M., Dahl, R., & Lundqvist, R. (1981). Influence ofrelative humidity 
and repeated exercise on exercise-induced bronchoconstriction. Allergy, 36, 
463-470. 
Hill, E.A., Davies, S., & Geary, M. (1976). Salmefamol and salbutamol in exercise-
induced asthma children. British Journal of Diseases of the Chest, 70, 78-82. 
Hindle, M., Newton, D.A.G., & Chrystyn, h. (1993). Investigations of an optimal 
inhaler technique with the use of urinary salbutamol excretion as a measure or 
relative bioavailability to the lung. Thorax, 48, 607-610. 
Howarth, P.H., Durham, S.R., Lee, T.H., Kay, B., Church, M.K., & Holgate, S.T. 
(1985). Influence of albuterol, cromolyn sodium and ipratropium bromide on 
the airway and circulating mediator responses to allergen bronchial 
provocation in asthma. American Review of Respiratory Diseases, 132, 986-
992. 
Jones, R.S., Buston, M.H., & Wharton, M.J. (1962). [No title/. British Journal of 
Dieseases of the Chest. 56, 78. 
Kaliner, M., Eggleston, P., & Mathews, K. (1987). Techniques fro the prevention of 
allergies induced asthma. Journal of the American Medical Association, 
258(20), 2845-2855. 
Katz, R.M., & Pierson, W.E. (1988). Exercise-induced asthma: Current perspective. 
Advantage Sports medicine and Fitness, 1: 83-96. 
Konig, P. (1985). Spacer devices used with metered-dose inhalers: Breakthrough or 
Gimmick? Chest, 88(2), 276-284. 
63 
L 
McFadden, E.R. (1983). Respiratory heat loss and water exchange: physiological and 
clinical implications. Journal of Applied Physiology, 54, 331-336 
McFadden, E.R.,Lyons, H.R. (1968). Arterial blood gas tension in asthma. New 
England Journal of Medicine, 12: 1027. 
McArdle, W.D., Katch, F.I., & Katch, V.L. (1996). Exercise physiology. Energy, 
nutrition and human performance. (41h ed.) Malvern, Philadelphia: Lea & 
Febiger 
McKenzie, D.C., Rhodes, E.C., Stirling, D.R., Wiley, J.P., Dunwoody, D.W., 
Filsinger, I.B., Jang, F., & Stevens, A. (1983). Salbutamol and treadmill 
performance in non-atopic athletes. Medicine and Science in Sports and 
Exercise, 15(6), 520-522. 
Morton, A.R. Asthma. In: Bloomfield, J., Fricker, P.A. & Fitch, K. (1992). Textbook 
of Science and Medicine in Sport. Victoria: Blackwell Scientific Publications. 
pp. 535-545. 
Morton, A.R., & Fitch, K.D.(1992). Asthmatic drugs and competitive sport; an 
update. Sports Medicine. 14(4), 228-242. 
Morton, A.R., & Fitch, K.D. Exercise Induced Asthma. In: Skinner, J.S. (1993). 
Exercise testing and exercise prescription for special cases: Theoretical basis 
and clinical application. (2nd ed). Philadelphia; Lea and Febiger. 
Morton, A.R., Fitch, K.D., & Hahn, A.G. (1981). Physical activity and the asthmatic. 
The Physician and Sportsmedicine. 9(3), 51-63. 
Morton, A.R., Lawrence, S.R., Fitch, K.D., & Hahn, A.G. (1983). Duration of 
exercise in the provocation of exercise-induced asthma. Annals of Allergy, 
li, 530-534. 
National Asthma Campaign. ( 1996). Asthma Management Handbook. Melbourne; 
NAC ltd. 
National Heart, Lung and Blood Institute ( 1992). International Consensus Report on 
Diagnosis and Treatment of Asthma Maryland: Bethesda USA. 
Newhouse, M.T (1997). Inhalation drug delivery from seven different spacer devices. 




Newhouse, M.T., & Dolovich, M. (1987). Aerosol therapy ofreversible airflow 
obstruction, concepts and clinical applications. Chest, 91(5), 58S-64S. 
Newman, S.P., Clark, AR., Talaee, N., & Clarke, S.W. (1989). Pressurised aerosol 
deposition in the human lung with and without an "open" spacer device. 
Thorax, 44, 706-710. 
Newman, S.P., Moren, F., Pavia, D., Little, F., & Clarke, S.W. (1981). Deposition of 
pressurised aerosols inhaled through extension devices. American Review of 
Respiratory Disease, 124, 317-320. 
Newman, S.P., Millar, AB., Lennard-Jones, T.R., Moran, F., & Clark, S.W. (1984). 
Measurement of pressurised aerosol deposition with nebuhaler space devices. 
Thorax, 39, 935-941. 
Noviski, N., Bar-Yishay, E., Gur, I., & Godfrey, S. (1987). Exercise intensiy 
determines and climatic conditions modify the severity of exercise-induced 
asthma. American Review of Respiratory Disease, 136, 592-594. 
O'Cain, C.F., Dowling, N.B., Slutsky, AS., Hensley, M.J., Strohl, K.P., McFadden, 
E.R., & Ingram, R.H. ( 1980). Airway effects of respiratory heat loss in normal 
subjects. Journal of Applied Physiology, 49(5), 875-880. 
Orehek, J., Gayrard, P., Grimaud, C.H., & Charpin, J. (1976). Patient error in use of 
bronchodilator metered aerosols. British Medical Journal, 1, 76. 
Otis, AB. (1964). Quantitative relationships in steady state gas exchange. Handbook 
of Respiration. 3( 1 ), 221. 
Papalia, S. (1991). The effects of salbutamol on pulmonary function and physical 
performance of non-asthmatic athletes. Unpublished Masters Thesis, The 
University of Western Australia, Perth WA. 
Patterson, LC., & Crompton, G.K. (1976). Use of pressurised aerosols by asthmatic 
patients. British Medical Journal, i, 76-77. 
Pedersen, J.Z., & Bundgaard, A (1983). Comparative efficacy of different methods of 




Rasmussen, B.S., Elkjaer, P., & Juhl, B. (1988). Impaired pulmonary and cardiac 
function after maximal exercise, Journal of Sports Sciences, 6, 219-228. 
Rees, J., & Price, J. (1989). ABC of Asthma. London: British Medical Association 
Rivlin, J., Mindorff, C., Reilly, P.,& Levison, H. (1984). Pulmonary response to a 
bronchodilator delivered from three inhalation devices. Journal of Pediatrics, 
104(3), 470-473. 
Rossi, L. (1995). Comparison of cool-air breathing aid and terbutaline in the 
prevention and amelioration of exercise-induced asthma. Unpublished 
Masters Thesis, The University of Western Australia, Perth WA. 
Schmidt, A., Diamant, A., Bundgaard, A., & Masden, P.L. (1988). Ergogenic effect if 
inhaled beta-2-agonists in asthmatics. International Journal of Sports 
Medicine, 9(5), 338-340. 
Silverman, M., & Anderson, S.D. (1972). Standardisation of exercise tests in 
asthmatic children. Archives of Disease in Childhood, 47, 882-889. 
Sly, R.M. (1970). Exercise-related changes in airway obstruction. Frequency and 
clinical correlates in asthmatic children. Annals of Allergy, 28, 1-16. 
Sly, R.M., Puapan, P., Ghazanshahi, S., & Midha, R. (1975). Exercise-induced 
bronchospasm evaluation of albuterol aerosol. Annals of Allergy, 34, 7-14. 
Stark., RD., & Gambles, S.A. (1981). Effects of salbutamol, ipartropium bromide 
and disodium cromoglycate on breathlessness induced by exercise in normal 
subjects. British Journal of Clinical Pharmacology, 12, 497-501. 
Sterling, G.M. (1968). The mechanism of bronchoconstriction due to hypocapnia in 
man. Clinical Scientist, 34: 227 
Swimburn, P. (1976). Asthma Definition. A symposium on Asthma. Proceedings of 
meetings held in Auckland, Wellington, Dunedin and Christchurch. (pp9-11 ). 
Tobin, M.T., Jenouri, G., Danta, I., Kim, C.S., Watson, H., & Sackner, M.A. (1982). 
Response to bronchodilator drug administration by a new reservoir aerosol 
delivery system and a review of other auxiliary systems. American Review of 
Respiratory Diseas, 126, 670-675. 
66 
Togias, A.G., Naclerio, R.M., Proud, D. Fish, J.E., Adkinson, N.F., Kagey-Sobotka, 
A., Norman, P.S., & Lichtenstein, L.M. (1985). Nasal Challenge with cold, 
dry air results in release of inflammatory mediators. Journal of Clinical 
Investigation, 76, 1375-1381. 
Vassalo, C.C., Gee, J.B.L.,& Domm, B.M. (1972). Exercise-induced asthma: 
Observations regarding hypocapnia and acidosis. American Review of 
Respiratory Diseases, 105: 742-49. 
Weiss, E.B., Segal, M.S., & Stein, M. (1985). Bronchial asthma, mechanisms and 
therapeutics. Boston; Little, Brown and Co. 
Wilhaber, J.H., Devadason, S.G., Eber, E., Hayden, M.J., Everard, M.L., Summers, 
Q.A., & LeSouef, P.N. (1996). Effect of electrostatic charge, flow, delay and 
multiple actuations on the in vitro delivery of salbutamol from different small 
volume spacers for infants. Thorax, 51, 985-988. 
Wilhaber, J.H., Devadason, S.G., Hayden, M.J., James, R., Dufty, A., Fox, R., 
Summers, Q.A., & LeSouef, P.N. (1996). Electrostatic charge in a plastic 
spacer device influences the delivery of salbutamol. European Respiratory 







Normalised Raw Data Collected for 5 Lung functions over 
three treatments 
Mean and Standard Deviations for Bronchial Lability results 
over 3 test periods. 
Mean and Standard Deviations for Decrement results over 3 
test periods. 
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RAW NORMALISED DATA FOR 5 LUNG FUNCTIONS. 
NB: Constrict and Dilate categories are based on FEVl values. 
Table Al. Normalised Raw Data Collected for 5 Lung functions over three treatments 
J MDI TREATMENT I 
IFEF2s-1s mins -13 -8 0 3 5 7 10 20 30 
1 constrict 100 100.44 115.11 122.22 116.44 102.22 112.44 100.44 100 
2 constrict 100 93.64 140.17 72.54 73.41 73.99 69.65 84.1 87.57 
3 dilate 100 114.71 122.55 116.67 113.07 109.15 110.46 110.46 106.86 
4 constrict 100 82.07 49.51 59.26 64.52 52.44 75.44 67.45 64.33 
5 constrict 100 118.55 90.32 78.23 84.68 91.13 97.58 103.23 120.16 
6 constrict 100 100.31 148.93 110.09 107.03 109.17 96.64 105.2 89.91 
7 dilate 100 101.88 111.53 103.53 99.53 95.29 101.18 99.53 103.76 
8 dilate 100 101.95 120.49 106.83 105.85 114.63 104.39 99.02 101.46 
9 constrict 100 141.67 170.83 148.61 153.82 150 153.13 148.26 161.81 
10 constrict 100 89.26 130.2 65.1 67.11 69.13 69.8 92.62 92.62 
11 dilate 100 108.41 123.36 119 116.82 115.26 121.81 116.51 122.12 
12 dilate 100 101.01 120.35 109.55 99.5 105.28 101.26 99.25 101.76 
13 dilate 100 101.65 107.76 100.47 104 102.35 100.24 103.53 106.82 
SPACER TREATMENT 
FEF2s.1s mins -13 -8 0 3 5 7 10 20 30 
1 constrict 100 101.69 116.88 102.53 89.45 82.28 93.25 100.84 100 
2 constrict 100 113.37 144.39 120.05 118.38 110.98 116.47 118.38 118.62 
3 dilate 100 112.15 115.89 108.72 103.74 107.17 104.36 109.66 113.08 
4 constrict 100 76.42 77.27 70.74 56.25 84.38 80.4 98.3 82.95 
5 constrict 100 173.91 138.04 126.09 132.61 136.96 118.48 146.74 161.96 
6 constrict 100 158.78 285.14 212.16 179.73 191.22 183.11 186.49 208.78 
7 dilate 100 105.85 108.91 103.82 103.56 101.78 105.34 99.24 101.02 
8 dilate 100 114.58 130.73 127.6 114.58 110.94 97.4 117.71 110.94 
9 constrict 100 126.86 140 135.14 138.57 139.43 136.57 144.86 142 
10 constrict 100 92.81 115.11 79.14 80.58 82.01 81.29 92.09 102.16 
11 dilate 100 113.68 122.19 113.07 118.54 120.67 120.06 117.33 123.1 
12 dilate 100 113.95 117.11 112.37 109.47 106.58 111.84 106.32 109.21 
13 dilate 100 103.69 114.29 102.76 100.46 108.53 104.15 106.91 105.76 
PLACEBO TREATMENT 
FEF2s.1s mins -13 -8 0 3 5 7 10 20 30 
1 constrict 100 97.5 94.58 97.92 76.25 75.83 104.17 85 88.75 
2 constrict 100 90.09 98.82 50 53.07 38.68 41.75 54.48 76.18 
3 dilate 100 106.15 112.31 100.31 94.15 97.23 94.46 99.08 98.15 
4 constrict 100 97.72 84.79 92.02 97.72 98.48 94.3 109.13 164.26 
5 constrict 100 82.3 93.81 41.59 47.79 50.44 53.1 68.14 72.57 
6 constrict 100 101.84 181.6 113.5 100.61 94.48 104.29 114.11 101.23 
7 dilate 100 99.71 103.48 97.39 98.84 95.65 96.52 94.2 95.36 
8 dilate 100 106.54 110.75 102.34 98.6 97.2 91.12 95.79 100.47 
9 constrict 100 91.16 91.71 74.03 40.61 56.91 74.86 99.72 111.33 
10 constrict 100 111.72 138.28 56.25 57.03 55.47 54.69 58.59 64.84 
11 dilate 100 98.15 109.23 100.92 102.15 101.23 99.38 103.69 112 
12 dilate 100 97.33 111.47 104.8 97.87 99.2 101.07 96.53 96 








FEVl mins -13 -8 0 3 5 7 10 20 30 
1 constrict 100 101.63 104.61 106.5 104.61 100.54 102.98 104.34 100.81 
2 constrict 100 98.66 109.41 88.71 88.71 89.25 87.63 94.62 97.04 
3 dilate 100 103.56 101.78 104.27 103.56 102.85 102.14 101.78 105.34 
4 constrict 100 96.06 73.09 87.47 89.56 83.53 94.9 85.61 89.56 
5 constrict 100 116.76 104.86 93.51 94.05 97.84 103.78 109.19 114.59 
6 constrict 100 97.19 109.21 101.28 100.77 102.05 95.14 95.91 87.21 
7 dilate 100 101.58 94.72 101.32 100 98.42 101.32 101.06 100 
8 dilate 100 105.04 111.51 107.91 108.27 109.71 108.63 103.96 104.32 
9 constrict 100 114.38 116.61 115.97 114.06 117.25 117.89 117.57 122.68 
10 constrict 100 91.09 112.02 74.81 73.26 76.36 76.74 92.25 94.57 
11 dilate 100 104.72 108.33 106.67 106.39 105.83 107.5 108.06 106.94 
12 dilate 100 101.02 106.14 106.39 103.07 102.3 102.56 101.02 101.79 
13 dilate 100 103.61 103.89 101.94 103.89 101.67 98.89 102.5 101.67 
SPACER TREATMENT 
FEVl mins -13 -8 0 3 5 7 10 20 30 
1 constrict 100 105.04 105.88 99.16 93.28 86.83 84.87 98.04 100.56 
2 constrict 100 103.95 106.58 106.84 106.05 102.11 104.74 106.84 107.63 
3 dilate 100 104.95 107.07 105.65 104.95 106.71 107.07 105.3 104.95 
4 constrict 100 86.42 85.93 81.73 71.36 91.6 89.14 95.31 88.64 
5 constrict 100 153.16 135.44 126.58 130.38 134.81 123.42 143.67 138.61 
6 constrict 100 134.41 192.31 168.02 155.47 156.28 150.61 147.37 158.7 
7 dilate 100 106.37 98.34 106.93 104.71 106.09 103.6 104.16 105.82 
8 dilate 100 109.26 118.52 115.56 113.7 111.85 106.67 117.41 110.37 
9 constrict 100 108.04 96.73 106.25 109.82 112.5 111.01 112.5 113.1 
10 constrict 100 97.69 107.31 81.92 79.62 83.46 88.08 93.85 101.92 
11 dilate 100 105.83 106.39 107.22 107.5 108.33 107.78 107.78 108.06 
12 dilate 100 103.7 109.26 107.67 105.03 104.23 106.08 103.7 104.5 
13 dilate 100 103.06 105.01 104.18 102.51 105.57 104.46 104.74 103.62 
PLACEBO TREATMENT 
FEVl mins -13 -8 0 3 5 7 10 20 30 
1 constrict 100 99.11 99.11 105.33 96.75 90.24 104.14 96.75 98.22 
2 constrict 100 95.83 98.44 75 74.74 64.06 67.45 76.04 89.32 
3 dilate 100 97.63 100 98.64 97.97 99.66 100.34 98.64 98.31 
4 constrict 100 106.27 93.42 100.63 104.39 107.21 105.64 112.54 136.68 
5 constrict 100 87.29 92.82 41.44 46.41 51.38 55.25 67.96 75.69 
6 constrict 100 98.5 136.09 103.01 97.37 92.86 100.75 105.64 107.14 
7 dilate 100 100.64 99.68 101.93 102.57 100.96 102.89 99.68 101.29 
8 dilate 100 103.79 107.93 106.9 105.17 104.14 98.28 102.76 104.48 
9 constrict 100 97.6 83.53 74.25 56.59 64.97 78.44 94.61 104.79 
t 
10 constrict 100 105.33 113.78 65.33 63.11 61.33 62.22 72.44 81.33 
11 dilate 100 99.44 103.37 99.72 101.4 101.69 101.12 102.53 103.93 
12 dilate 100 99.19 107.55 105.39 103.5 101.62 103.23 97.84 96.77 
13 dilate 100 96.42 99.67 98.05 100.65 99.02 100.33 99.02 96.74 
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MDI TREATMENT 
FVC mins -13 -8 0 3 5 7 10 20 30 
1 constrict 100 103.16 100.53 100 102.81 101.58 99.65 103.86 101.93 
2 constrict 100 100.44 93.44 97.16 96.5 96.72 97.59 99.12 100.88 
3 dilate 100 99.4 91.54 97.58 97.89 95.47 96.68 95.77 100.6 
4 constrict 100 98.82 91.55 99.61 98.43 99.21 96.27 96.27 98.62 
5 constrict 100 112.64 113.72 101.81 99.64 102.17 106.14 110.11 109.03 
6 constrict 100 97.19 99.4 99 100.2 101.2 95.58 94.18 86.55 
7 dilate 100 100.25 92.84 97.53 97.04 99.26 100.25 99.51 100.25 
8 dilate 100 106.61 107.94 108.47 110.58 107.94 110.05 106.35 104.76 
9 constrict 100 107.01 101.3 106.75 104.16 109.61 109.09 109.35 110.39 
10 constrict 100 93.27 101.16 83.99 80.28 83.29 84.92 94.9 96.06 
11 dilate 100 102.91 98.66 101.34 101.57 102.01 102.24 103.13 101.12 
12 dilate 100 100.86 98.71 103.43 102.79 100.21 101.93 101.29 101.72 
13 dilate 100 103.37 101.69 101.45 103.13 102.41 99.52 102.65 100.72 
SPACER TREATMENT 
FVC mins -13 -8 0 3 5 7 10 20 30 
1 constrict 100 103.78 102.52 97.84 97.66 97.3 96.76 96.04 96.58 
2 constrict 100 101.14 92.5 98.86 101.14 98.18 98.64 101.14 102.27 
3 dilate 100 102.47 96.6 101.85 102.16 104.63 105.25 101.85 101.54 
4 constrict 100 100.19 97.09 96.9 100 100.39 100.19 98.84 98.26 
5 constrict 100 131.6 123.79 118.96 120.82 121.93 117.1 129.37 117.47 
6 constrict 100 113.18 147.01 139.55 133.08 131.09 126.12 121.39 128.11 
7 dilate 100 102.67 93.2 103.16 97.33 101.21 99.76 101.7 101.94 
8 dilate 100 106.08 112.17 109.52 111.64 110.32 108.99 114.29 108.73 
9 constrict 100 104.87 94.62 97.18 100.51 105.13 102.05 103.08 105.13 
10 constrict 100 97.06 101.47 84.87 80.46 84.87 89.5 93.7 96.85 
11 dilate 100 103.41 98.86 105.68 102.27 103.41 102.73 102.5 102.5 
12 dilate 100 101.75 104.6 105.47 104.16 103.72 104.16 102.63 102.63 
13 dilate 100 102.66 101.69 104.35 102.9 104.83 103.14 104.11 102.17 
PLACEBO TREATMENT 
FVC mins -13 -8 0 3 5 7 10 20 30 
1 constrict 100 104.92 101.97 107.48 104.72 100.98 103.35 102.17 105.91 
2 constrict 100 96.18 92.81 88.99 86.29 80.67 84.04 88.76 94.16 
3 dilate 100 98.84 85.76 96.51 98.26 99.42 100 98.26 97.97 
4 constrict 100 95.38 95.58 97.99 99.4 101.61 103.21 99.6 103.61 
5 constrict 100 91.72 93.79 42.76 46.55 55.86 63.1 77.59 84.83 
6 constrict 100 98.28 115.69 98.04 97.3 93.63 101.47 104.41 111.76 
7 dilate 100 102.92 95.92 100.58 102.62 100.87 101.17 100.87 101.46 
8 dilate 100 103.06 107.65 109.95 109.44 109.95 107.14 109.18 107.4 
9 constrict 100 101.58 83.42 76.84 68.42 69.47 82.37 95 101.84 
10 constrict 100 101.31 102.35 84.6 74.93 73.89 79.11 91.12 97.91 
11 dilate 100 101.15 99.31 98.62 102.07 102.53 102.99 104.14 100.46 
12 dilate 100 100 104.49 105.39 105.17 102.47 103.82 97.75 98.43 
13 dilate 100 96.39 99.44 102.5 102.5 100.28 101.39 100.28 98.89 
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I MDI TREATMENT 
I MEFSO mins -13 -8 0 3 5 7 10 20 30 
1 constrict 100 111.54 115.77 138.46 116.54 114.62 103.46 120.77 102.69 
2 constrict 100 93.28 134.33 74.88 76.12 75.62 69.15 84.58 90.3 
3 dilate 100 102.36 105.77 102.89 98.95 89.76 93.96 93.18 88.45 
4 constrict 100 103.6 44.18 60.96 68.49 48.63 68.49 80.82 54.11 
5 constrict 100 126.03 95.21 76.03 82.88 86.99 100 102.74 115.75 
~ 6 constrict 100 101.01 152.91 106.33 99.24 106.33 100 107.34 91.9 
I 7 dilate 100 100.91 112.3 103.19 100.46 97.04 101.59 101.59 107.29 ' 
8 dilate 100 105.45 105.06 102.33 106.61 112.45 108.95 96.89 103.5 
9 constrict 100 148.16 165.03 162.27 159.82 163.19 163.5 165.64 156.75 
10 constrict 100 90.45 125.28 67.98 60.67 65.17 65.17 80.9 90.45 
11 dilate 100 109.83 121.91 117.7 112.64 117.98 118.82 115.45 121.63 
12 dilate 100 100.66 112.11 101.98 92.95 99.78 92.73 93.17 103.74 
13 dilate 100 90.36 97.16 96.22 95.27 100.38 98.87 99.24 103.4 
I SPACER TREATMENT 
t- I MEFSO mins -13 -8 0 ' 3 5 7 10 20 30 
1 constrict 100 105.24 117.23 100.37 98.5 85.39 102.25 110.11 110.49 
2 constrict 100 113.98 136.42 111.61 118.31 113.39 112.99 106.3 113.39 
3 dilate 100 105.19 97.4 95.06 88.05 91.69 88.05 93.77 101.04 
4 constrict 100 84.75 75.75 74 53.75 82 85 99.25 86.5 
5 constrict 100 196.15 146.15 134.62 138.46 146.15 128.85 159.62 169.23 
6 constrict 100 172.67 313.66 232.3 206.83 209.94 200.62 193.79 225.47 
7 dilate 100 104.33 108.41 106.97 101.68 98.8 102.4 104.81 97.6 
' 8 dilate 100 118.1 130.17 125.43 119.83 119.4 106.9 99.14 135.78 
9 constrict 100 146.41 146.67 136.41 141.54 147.95 143.08 141.79 139.49 
10 constrict 100 104.93 128.87 97.18 88.73 90.14 91.55 95.77 125.35 
11 dilate 100 110.68 119.18 106.03 112.33 124.38 120.27 109.04 120.27 
12 dilate 100 107.46 101.81 99.6 106.85 99.8 95.16 99.6 98.19 
13 dilate 100 93.77 103.74 98.75 93.77 100.71 101.78 99.82 97.51 
I PLACEBO TREATMENT 
I MEFSO mins -13 -8 0 3 5 7 10 20 30 
1 constrict 100 104.33 116.25 102.53 84.12 73.29 88.81 83.75 87 
2 constrict 100 87.22 94.93 50.91 54.16 38.34 41.38 56.39 73.83 
3 dilate 100 101.33 105.33 97.33 88.27 88.8 90.4 94.93 93.33 
4 constrict 100 111.11 87.81 88.53 111.11 99.64 91.4 115.05 166.31 
5 constrict 100 82.81 89.06 39.06 45.31 46.88 50.78 65.63 71.09 
6 constrict 100 101.09 183.61 114.75 102.73 92.35 106.01 123.5 109.29 
7 dilate 100 97.79 106.63 99.17 97.79 95.86 95.86 91.99 96.69 
8 dilate 100 104.18 100.38 106.46 145.25 93.54 84.79 95.82 101.9 
9 constrict 100 97.55 97.06 74.26 41.67 57.35 78.43 101.47 115.2 
10 constrict 100 118.57 136.43 59.29 61.43 54.29 52.86 60 75 
11 dilate 100 103.63 103.35 100.84 105.87 102.23 101.12 109.5 112.57 
12 dilate 100 93.26 103.37 113.26 103.15 102.02 98.65 102.02 100.9 




PEFR mins -13 -8 0 3 5 7 10 20 30 
1 constrict 100 98.07 73.89 89.1 78.77 66.63 74.69 71.17 67.99 
2 constrict 100 101.37 108.24 92.29 92.08 93.88 82.47 94.51 96.73 
3 dilate 100 105.84 113.18 102.45 107.53 104.52 105.65 106.78 99.62 
4 constrict 100 97.89 61.27 90.56 93.52 88.03 97.46 78.03 91.55 
5 constrict 100 113.18 106.35 99.29 85.65 89.18 92 100.47 113.65 
6 constrict 100 67.24 71.45 77.56 73.93 71.78 75.83 71.95 76.16 
7 dilate 100 94.05 100.96 96.3 108.04 77.17 91.48 99.84 84.57 
8 dilate 100 106.89 106.09 108.34 98.41 106.36 110.2 108.61 109.67 
9 constrict 100 92.33 89.64 103.23 97.31 100 104.71 100.67 104.17 
10 constrict 100 102.62 113.51 74.6 76.81 84.48 72.38 98.59 114.11 
11 dilate 100 95.01 104.2 98.42 93.82 95.4 90.28 101.71 97.77 
12 dilate 100 93.39 95.87 95.16 97.64 92.8 94.92 94.57 98.58 
13 dilate 100 97.52 94.04 89.4 116.39 102.81 101.32 93.21 105.96 
SPACER TREATMENT 
PEFR mins -13 -8 0 3 5 7 10 20 30 
1 constrict 100 129.32 109.51 113.4 94.95 83.88 76.7 106.21 112.04 
2 constrict 100 82.2 105.73 93.19 86.38 78.14 81.36 87.34 79.57 
3 dilate 100 103.53 115.58 111.5 111.69 110.95 103.71 105.75 106.49 
4 constrict 100 68.24 72.01 62.45 56.26 79.54 66.76 68.37 71.74 
5 constrict 100 161.75 165.96 161.75 156.84 143.86 168.42 178.6 177.54 
6 constrict 100 149.14 203.3 151.18 143.96 154.16 149.76 143.01 164.68 
7 dilate 100 112.6 107.52 93.29 110.37 114.02 121.14 89.43 126.63 
8 dilate 100 104.03 114.09 110.06 110.44 108.81 111.7 109.06 109.06 
9 constrict 100 103.52 98.96 94.91 100.78 98.83 101.83 105.61 96.08 
10 constrict 100 99.43 131.24 90.86 84.38 84 89.71 100 103.81 
11 dilate 100 101.07 103.33 103.73 101.46 96.67 103.2 101.73 97.87 
12 dilate 100 87.6 115.44 111.74 107.26 101.32 101.72 106.99 111.48 
13 dilate 100 92.06 93.59 91.76 90.08 107.18 112.21 102.9 90.69 
PLACEBO TREATMENT 
PEFR mins -13 -8 0 3 5 7 10 20 30 
1 constrict 100 87.9 129.44 156.85 129.44 96.17 120.36 127.42 152.62 
2 constrict 100 117.1 124.69 104.28 100.28 86.62 87.17 75.59 98.34 
3 dilate 100 101.31 109.01 94.93 95.31 100.94 95.5 104.69 100.94 
4 constrict 100 187.1 105.84 129.93 117.76 130.17 131.14 144.53 169.1 
5 constrict 100 88.54 78.04 37.47 40.57 45.11 47.73 58.71 66.83 
6 constrict 100 96.66 111.13 89.15 93.88 87.9 100 95.55 100.83 
7 dilate 100 105.79 93.75 98.61 107.18 103.7 105.09 111.11 111.11 
8 dilate 100 105.15 106.08 102.38 101.06 98.81 101.72 99.74 107 
9 constrict 100 96.03 74.42 66.62 43.37 53.63 68.67 77.02 89.88 
10 constrict 100 92.43 97.1 69.49 65.03 62.14 71.27 69.04 81.51 
11 dilate 100 100.4 107.52 102.82 96.91 99.33 98.79 97.32 99.33 
12 dilate 100 93.25 92.27 92.02 90.31 93.99 92.76 88.1 94.85 
13 dilate 100 92.9 86.89 72.68 94.17 79.42 90.71 86.89 92.71 
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Table A2 Mean and Standard Deviations for Bronchial Lability results over 3 test 
.Q_eriods. 
Pulmonary 
MDI fu?_acer Placebo 
function variable 
mean(± SD) mean (±SD) mean(± SD) 
FVC (1) 
10.61# 12.98 24.45# 
(±6.13) (± 7.93) (± 17.90) 
FEV1 (1) 
20.17 24.04 37.36 * 
(±12.37) (± 13.22) (± 17.54) 
FEF2s-1s l.min-1 
46.86 44.77 55.60 
(± 20.03) (± 30.80) (± 27.23) 
PEFR l.min-1 
28.27# 37.45 53.04# 
(± 12.60) (± 18.49 (± 18.67) 
MEFso l.min-1 
43.97 47.81 58.80 
(± 18.35) (±35.67) (± 24.60) 
# indicates significance between the MDI and placebo treatments to the p < 0.05 level. 
Table A3. Mean and Standard Deviations for Decrement results over 3 test .Q_eriods. 
Pulmonary function 
MDI fu?_acer Placebo 
variable 
mean(± SD) mean(± SD) mean(± SD) 
FVC (1) 
6.98 5.64 20.72 
(± 7.56) (± 6.70) (± 19.93) 
FEV1 (1) 
12.19 9.62 28.58 
(± 11.24) (± 11.72) (± 20.71) 
FEF2s-1s l.min-1 
19.64 11.76 38.48 
(± 20.25) (± 16.80) (± 23.22) 
PEFR .min-1 
25.17 15.71 28.19 
(± 11.76) (± 15.74) (± 24.98) 
MEF50 1 min-
1 20.90 10.30 37.74 
(±21.04) (± 17.01) (± 24.64) 
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APPENDIX B 
Consent Documents and Subject Information/instruction forms 
1. Initial Subject Information Form. 
2. Covering Letter 
3. Consent Form. 
4. Medical Questionnaire. 




School of Biomedical and Sports Sciences 
Edith Cowan University 
A study conducted by Professor A.R. Morton and Mr. D. G. Reed to investigate the 
efficacy of a 'spacer' in the delivery of salbutamol for the prevention of Exercise 
Induced Asthma. 
WE REQUIRE ACTIVE INDIVIDUALS WHO UNDERTAKE REGULAR 
EXERCISE WHO ARE 18-35 YEARS OF AGE WHO REGULARLY EXHIBIT 
EXERCISE INDUCED ASTHMA 
You would be required to attend 3 test sessions, all at the Joondalup campus of Edith 
Cowan University each lasting for 1 hour. All testing will be carried out by qualified 
personnel. 
All sessions will involve the initial testing of lung function using a spirometer and 
then the administration of an inhaled substance followed by an 8 minute run on a 
motor driven treadmill. Lung function will then be measured intermittently over a 
period of 30 minutes post exercise. 
On each of the visits, a different protocol will exist for the administration of the 
inhaled substance. On 2 of the 3 sessions, salbutamol (Ventolin) will be inhaled via a 
Metered Dose Inhaler or a 'Spacer' devise. The other visit will incur no active drug 
administration. (placebo) 
It is the purpose of this study to induce a mild asthmatic bronchospasm and study the 
potential effect that differing delivery systems have on post exercise lung function. 
During the test, your heart rate will be monitored by a Polar heart rate monitor and the 
perceived exertion via the Borg Scale. Discomfort may be experienced with this study 
during the 8-minute treadmill run (mild fatigue) with possible side-effects caused by 
the bronchospasm also generating some uncomfortable symptoms. Heart rate will be 
monitored at all times and if at any stage during the test, your asthma becomes 
distressing, or it takes longer than usual to recover, you will be given your usual 
'reliever' medication. The exercise challenge used during this study is a safe and 
routine procedure, which has been performed many hundreds of times under similar 
laboratory conditions conducted by Professor Morton (supervisor) 
The treadmill running test will consist of a multistage continuous exercise test that 
will last for 8 minutes and correspond to a speed and gradient that generates a 75%-
85% predicted maximal heart rate. (220- age). No warm up will be given; however, 
the first 2 -3 minutes will be easy enough to generate desired preparation. 
Lung function will be measured pre-medication, then five minutes later it will be 
repeated (post-medication pre-exercise.) Following 8 minutes of exercise, lung 
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function will be measured immediately, then after 3, 5, 7, 10, 20 and 30 minutes post 
exercise. 
Salbutamol is the most commonly prescribed asthma medication and is used regularly 
by asthmatics to prevent EIA, occasionally side effects of palpitation and muscle 
tremor may occur. A doctor will be on call during all testing sessions. 
It is your right to withdraw your consent at any time and to discontinue your 
participation in the study generally or in any specific aspect of it. Data obtained from 
the results of the tests to be conducted will be placed in a thesis; names of individual 
subjects will not be used. 
You will be provided with your test results that will be explained and compared to 
norms for your age, height, sex and weight. You will also gain clearer understanding 
of the management of your exercise-induced asthma. 
Please note that all subjects must be salbutamol users on a regular basis. Participation 




Tuesday, OJ September 1998 
Dear, 
Thankyou very much for volunteering your time to be a part of this study that aims to 
distinguish the most effective delivery system of Ventolin for the prevention of 
exercise induced asthma. The ramifications of this research will give asthmatics 
reliable information on which delivery system best prevents EIA. (between Metered 
dose inhalers and spacers). 
It is important to carefully read all documents within this package and truthfully 
complete all enclosed forms. 
Forms that will require your attention are: 
• Medical Questionnaire 
• Consent Form 
• Covering letter (GP's phone number and name) 
During the next few days, you will be required to obtain medical clearance that will 
be conducted by the ECU Joondalup medical practitioner. This service is only 
available from 9.00 am to 12.30pm each weekday. I will call you to organise times in 
the near future. (This medical will incur no cost to you) 
All forms must be completed by the time of the medical and will be collected from 
you at this time. Could you please fill in the name of your Doctor and his/her phone 
number in case of emergency and for consultation on your participation in this study. 
I do realise how busy you are so it cannot be emphasised how grateful I am that you 
are giving your time to this research. 
Thanking you again 
David Reed 
Name of Doctor _______________ _ 
Phone number _______________ _ 
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CONSENT FORM 
School of Biomedical and Sports Sciences 
Edith Cowan University 
I, the undersigned. ______________________ _ 
Of ____________________________ _ 
Do freely and voluntarily give consent to be a subject in a study conducted by Mr. David 
Reed and Prof. Alan Morton to investigate the efficacy of the 'spacer' in the delivery of 
salbutamol (Ventolin ™) for the prevention of exercise-induced asthma. 
I have been informed that this medication is commonly prescribed and used regularly by 
asthmatics to prevent and reverse attacks of asthma. I have been informed that occasionally 
side effects of palpitation and muscle tremor may occur. A doctor will be on call during all 
testing sessions. 
I declare that the purpose of this study has been fully explained to me and that I understand 
them. I realise that I will be required to attend 3 sessions all at the Physiology Laboratory at 
Edith Cowan University, Joondalup. During each of my 3 visits, I will be required to 
complete an 8-minute running exercise on a motor driven treadmill at a rate of 75-85% of my 
predicted maximal heart rate. Before each of these tests, either a placebo, salbutamol via a 
metered dose inhaler or salbutamol via a 'Spacer' will be administered by inhalation through 
the mouth. (A Spacer is a clear plastic cylinder approximately 20 cm long which combines air 
and medication to aid in the full inhalation of the salbutamol). 
Before and after the test, my lung function will be measured a total of 10 times which requires 
me to forcefully exhale into a spirometer for a short period of time. 
Whilst I hereby indicate my willingness to act as subject in the study, I retain the right to 
withdraw my consent at any time and to discontinue my participation in the study generally or 
in any specific aspect of it. I understand that should I have any questions concerning this 
project they can be directed to David Reed. 
I wave all possible responsibility from Edith Cowan University and participate at my own 
risk. Finally, I declare that any research data obtained from the results of the test to be 
conducted can be published in scientific papers, provided my name is not used. 
Subject: (sign) 
Witness: (sign) 
Date: ___________ _ 
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Medical Questionnaire 
The following questionnaire is designed to establish a background of your medical history, and identify 
any injury or illness that may influence your testing or performance. 
Please answer all questions as accurately as possible and if you are unsure about any thing please ask. 
All information provided is strictly confidential. 
. Personal Details 
Name: 
DOB: Sex: 
Height: _____ _ Weight: 
Medical History 
Have you ever had, or do you currently have any of the following? 










Any infectious diseases 
Are you currently on any medications? 
Have you had the flu in the last two 
weeks? 
Have you recently had any injuries or 
accidents? 
















Do you have any recurring muscle or 
joint injuries? 
Is there any other condition not 
previously mentioned which may affect 









Do you exercise regularly? 




Do you smoke tobacco or any other nicotine 
products 
If YES please how much per day? 
Do you consume alcohol? 
If YES how many standard drinks per week? 
Do you consume tea and or coffee? 
If YES how many cups per day? 
Do you take any recreational drugs? 











I acknowledge that the information provided on this form, is to the best of my knowledge, a true and 





Preparation for and the performance of any scientific test must be controlled to ensure 
consistency especially when dealing with multiple tests performed by the same 
subject. As is the case with this research, subjects will be required to undertake 
similar tests over a period of 1 to 2 weeks. 
The aim of this study is to examine the effects that differing delivery protocols of 
ventolin have on bronchoconstriction post exercise. It is therefore necessary to 
maintain similar circumstances during each test which is in some cases the 
responsibility of the subject. Below is a list of 'constants' that you as a subject should 
endeavour to adhere to prior to any test: 
Pre-test activities 
• Please ensure that all foodstuff consumption prior to test is identical in terms of 
time and type as well as quantity. 
Other factors of consideration: 
• Food consumption prior must be similar for a period of no less than 12 hours 
• Maintain same exercise patterns - no exercise 24 hours prior to test 
• Keep same sleeping patterns 
• Consume no caffeine products (coffee, chocolate or Coke) 
Test activities 
For the test, please regulate and repeat: 
• Clothing worn= shoes (runners), shorts, socks! All same please. 
• Drink no alcohol for 24 hours 
• No smoking for 12 hours 
• Fast for 3 hours prior 
• Be relaxed. (It's not as bad as it sounds!) 
The test facilitators will ensure that all the constants under their control will be 
maintained for all tests. It would be greatly appreciated if subjects could please do the 
same. The most important factor is that the same activities occur each week. Also 
record any details that you believe may become 'forgotten' by your next test. 
It is very important for you to take note of the list of drugs/treatments that are 
permitted prior to the test. These are listed on the attached form. 
Also note that your Doctor's (GP) phone number and name is required on the 
covering letter you received in this package so that contact can be made with 
him/her concerning your participation in this study. 
The information on this sheet is very important so please undertake the consistency 
procedures and understand that it's up to you! 




Instructions for MDI use & Spacer use. 
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Techniques for the administration of Aerosol salbutamol via the 
Metered Dose Inhaler (MDI). 
Subjects were instructed to follow the following steps in administering Ventolin via 
the MDI. 
1. Remove cap 
2. Shake inhaler 
3. Hold inhaler upright 
4. Tilt the head back 
5. Place the inhaler into the mouth 
6. Breath in and simultaneously activate the inhaler 
7. Continue to inhale slowly and deeply 
8. Hold breath for 10 seconds. 
For each aerosol treatment, 2 MDI actuations were administered 1 minute apart. 
To ensure optimal administration technique, subjects were verbally reminded of the 
correct technique and closely observed during all steps of treatment administration. 
Techniques for the administration of Aerosol salbutamol via the 
Spacer device (connected to a MDI). 
Subjects were instructed to follow the following steps in administering Ventolin via 
the Spacer device. 
1. Remove cap of MDI 
2. Shake inhaler 
3. Connect MDI to spacer at correct end. 
4. Tilt the head back 
5. Place the spacer uni-directional mouthpiece into the mouth 
6. Activate the inhaler with 2 actuations into chamber 
7. Breath in deeply and slowly 
8. Hold for 3 seconds 
9. Continue to inhale and exhale through mouthpiece for 3 breaths. 
To ensure optimal administration technique, subjects were verbally reminded of the 
correct technique and closely observed during all steps of treatment administration. 
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APPENDIX D 
Borg Scale of the Rate of Perceived Breathlessness 
'RPB' 
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BORG SCALE OF BREATHLESSNESS 
(RPB) 
nothing at all 





















Borg, G., & Noble, B. (1974). Perceived exertion. In: Exercise and Sports Sciences 
Review, J.H. Wilmore (Ed). New York: Academic Press. pp 131-153 
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APPENDIX E 
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Calibration of the Autospiral Autospirometer PAL 
Calibration of the Minato comprises of two separate calibration tasks. These are 
known as 'Offset calibration' and 'Volume calibration'. The manufacturers 
recommend that calibration occur once a week, however, for the purpose of this study, 
calibration was undertaken prior to each subject due to changes in temperature and 
humdity. 
Offset Calibration 
1. Depress [Cal] key to access the calibration display screen. 
2. Depress the [ 1] key to select offset calibration. 
3. Connect the filter end of the transducer (ie the non-mouth end), to a 
piston syringe, preferably with a 2 liter volume. Mov ethe piston 
several times. 
4. Next, cover the open end of the transducer with your hand (to 
prevent airflow) and depress the [START] key. 
5. Offset calibration will then be complete within 2 to 3 seconds. 
6. If airflow is dedtected, the word 'unusual' will appear and by 
pressing the [ce] key, the process is repeated. 
Volume Calibration 
This is performed straight after an offset calibration. 
1. Depress [Cal] key to change the screen to CALIBRATION display 
2. Depress [2] key to select Volume Calibration function. 
3. With syringe piston connected, press the [START] key 
4. Reciprocate the plunger from one end to the other moderately at 
least five times namely in order to draw five loops on the screen 
before you hear a short signal in approximately 20 seconds after the 
start of calibration. 
5. The calibration data is displayed on the screen and Volume 
Calibration is complete. 
6. The volume of the syringe calibrator can be changed within the 
owners menu prompt, however 2 liters is the recommended level. 
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'° 0 



















Heart Rate (b.min- I) 
HR pred max range: 
Data Coll, Subiect N A B C . 
2 3 4 5 6 7 8 
Post exercise---? 
Pre-ex Omin 3 min 5min 7min JO min 20 min 30 min 
D u dd . 
2 min 3 min 4 min Smin 6min 7min 8 min 
Data collected post . 
3 min 5min 7min JO min 20min 30min 
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Drugs That must be avoided prior to testing. 
Subjects should abstain from medication for 24 hours prior to testing. 
If this is not possible, the following guidelines should be adhered to. 
Do not take for 24 hours: 
• Cromolyn sodium (lntal) 
• Methyl xanthines 
• Antihistamines 
Do not take for 8 hours: 
• Aerosol corticoseroids (Becotide, Budesonide) 
• Anticholinergics 
Do not take for 12 hours: 
• Long acting beta-2 agonists 
Do not take for 4 hours: 
• Short acting beta-2 agonists (Ventolin) 
If you are unsure about any of these drugs, contact your doctor to discuss 
what medications you are on. 
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Raw Data for the reliability study of the Minato Autospirometer (n = 30) 
FEVl (I) FVC (1) FEF2s-1s PEFR MEFso (l.min"1) (l.min"1) (l.min"1) 
Subjec 
t 
test 1 test 2 test 1 test 2 test 1 test 2 test 1 test 2 test 1 test 2 
1 4.28 4.88 5.1 5.9 4.48 4.98 7.95 10.07 5.45 5.94 
2 3.54 3.73 4.02 4.28 4.4 4.34 12.13 12.62 5.4 5.07 
3 3.16 2.72 3.64 3.18 4.17 3.42 7.85 7.4 5.83 4.93 
4 2.76 2.36 3.49 2.97 2.42 2.08 7.07 6.19 2.89 2.5 
5 3.92 4.21 5.04 4.99 3.21 4.3 12.4 9.2 3.83 5.21 
5- 3.44 3.92 4.26 4.63 3.09 3.8 7.59 9.28 3.19 4.2 
7 4.39 4.44 5.42 5.4 4.13 4.35 9.26 8.74 4.44 5.06 
8 3.16 3.47 4 4.25 2.65 3.21 9.17 8.98 3.05 3.62 
9 4.88 5.03 5.58 5.68 5.86 5.96 11.75 12.19 7.36 7.48 
10 4.77 4.96 5.28 5.88 5.5 5.49 9.41 10.75 6.91 6.11 
11 3.06 3.09 3.9 3.97 2.63 2.49 9.01 9.35 3.09 2.94 
12 3.76 3.86 4.45 4.52 4.18 4.52 8.39 8.12 5.11 4.85 
13 3.48 3.51 4.02 4.2 3.5 3.77 8.09 8.89 4.65 4.72 
14 5.07 4.84 6.04 6.37 4.38 4.57 9.01 9.06 4.67 5.28 
15 4.82 4.73 5.67 5.56 5.09 4.96 10.51 9.66 6.02 5.48 
16 4.42 4.28 5.38 5.38 4.25 3.86 9.99 9.86 4.89 4.56 
17 4.75 4.89 5.9 5.58 5.08 5.24 10.56 11.11 5.79 5.91 
18 3.35 3.37 3.76 3.75 3.76 3.69 6.25 6.35 3.75 3.66 
19 5.25 5.24 5.85 5.97 6.09 5.78 11.49 10.81 7.25 7.01 
20 4.31 4.18 4.8 4.72 4.44 4.15 9.94 9.68 4.76 4.37 
21 4.76 4.8 5.56 5.29 4.89 5.8 11.15 11.1 5.08 6.7 
22 4.48 4.4 4.88 4.99 5.44 4.87 8.95 8.77 6.22 5.77 
23 4.49 4.52 5.77 5.74 3.85 3.89 10.06 10.63 4.42 4.58 
24 3.11 3.14 3.4 3.48 3.89 3.84 6.3 5.99 4.44 4.22 
25 4.62 4.77 5.29 5.28 4.97 5.5 11.04 9.41 5.58 6.91 
26 3.26 3.28 4.02 4.12 2.99 2.97 8.94 8.69 3.73 3.55 
27 3.47 3.46 4.25 4.21 3.21 3.24 7.98 7.88 3.52 3.62 
28 2.88 2.5 3.72 3.32 2.42 1.95 6.27 6.41 3.05 2.43 
29 2.63 2.72 3.3 3.31 2.81 2.58 5.69 6.58 2.51 2.95 
30 5.13 4.87 5.68 5.53 6.39 5.8 11.53 11.25 7.48 6.63 
Mean 3.98 4.01 4.72 4.75 4.14 4.18 9.19 9.17 4.81 4.88 
SD± 0.80 0.84 0.87 0.96 1.11 1.13 1.86 1.76 1.40 1.36 
Diff Tl -0.03 -0.03 -0.04 0.02 -0.06 
&T2 
ME 0.165 0.2 0.312 0.69 0.466 
V 4.14% 4.21% 7.49% 7.51% 9.62% -~---
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Test of within subjects effects 
Baseline values for lung functions 
Sum of sqrs df Mean sqr F sig p 
Test 10.456 2 5.228 2.912 0.093 
Lung*Test 8.91 8 1.114 3.097 0.007 
Baseline PEFR value 
Test A TestB 30.619 1 30.619 8.123 0.029 
Test A TestC 1.835 1 1.835 0.807 0.404 
HR ex A VS B VS C 
Test 4.46E-02 2 2.23E-02 0.003 0.997 
HR resrt A vs B vs C 
Test 111.867 2 55.933 1.865 0.197 
RPB ex A VS B VS C 
Test 1.249 2 0.624 2.16 0.137 
RPB rest A vs B vs C 6.109 2 3.054 3.763 0.054 
Test of within subjects Effects 
Lability 
FVC 
Test 767.251 2 383.625 4.145 0.043 
-·· 
Test of within subjects Contrasts 
TestC Test A 670.548 1 670.548 5.142 0.044 
TestC Test B 96.703 1 96.703 1.768 0.232 
Test of within subjects Effects 
FEV1 
Test 1138.03 2 569.015 3.641 0.58 
Test of within subjects Effects 
FEV1% 
Test 127.474 2 63.737 1.181 0.34 
Test of within subjects Effects 
FEF25-75 
Test 461.89 2 230.945 0.546 0.593 
Test of within subjects Effects 
PEFR 
Test 2194.112 2 1097.056 4.151 0.043 
Test of within-subjects contrast 
PEFR 
Test C Test A 2146.197 1 2146.197 8.699 0.026 
Test C Test B 47.915 1 47.915 0.17 0.694 
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Test of within subjects Effects 
MEFSO 
Test 828.314 2 414.157 0.846 0.453 
Sum of sqrs df Mean sqr F sig p 
Test of within subjects Effects 
Decrement 
FEV1 
Test 1481 2 740.5 2.876 0.095 
Test of within subjects Effects 
FVC 
Test 975.253 2 487.627 2.909 0.093 
Test of within subjects Effects 
FEV1% 
Test 147.448 2 73.724 0.917 0.426 
Test of within subjects Effects 
FEF25-75 
Test 2637.635 2 1318.818 3.387 0.068 
Test of within subjects Effects 
PEFR 
Test 593.573 2 296.786 0.648 0.54 
Test of within subjects Effects 
MEFSO 
Test 2679.497 2 1339.749 3.098 0.082 
T x T x s ANOVA time/test/subject. 
FEV1 
Sum of sqrs df Mean sqr F sig p 
Test 15370.13 2 7685.064 2.983 0.089 
Lung*Test 1385.377 12 115.448 2.514 0.008 
FEV1% 
Sum of sqrs df Mean sqr F sig p 
Test 2046.677 2 1023.338 2.142 0.16 
Lung*Test 219.366 12 18.28 0.68 0.765 
MEFSO 
Sum of sqrs df Mean sqr F sig p 
Test 55367.474 2 27683.74 4.062 0.045 
Lung*Test 2758.573 12 229.881 1.522 0.136 
Test of within subjects Contrasts 
MEFSO 
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Test C Test A 4679.262 1 4679.262 1.298 0.298 
TestC Test B 108231.1 1 108231.1 7.226 0.036 
MEFSO 3 minutes 9153.638 2 4576.819 4.082 0.044 
Contrast 
Test C Test A 3546.572 1 3546.572 2.552 0.161 
Test C Test B 8223.144 1 8223.144 7.853 0.031 
MEFSO 7 minutes 12179.778 2 6089.889 5.476 0.02 
Contrast 
Test C Test A 5624.055 1 5624.055 2.556 0.161 
Test C Test B 24347.358 1 24347.36 9.792 0.02 
MEFSO 10 minutes 9013.128 2 4506.564 6.58 0.012 
Contrast 
Test C Test A 3662.076 1 3662.076 2.855 0.142 
Test C Test B 7969.74 1 7969.74 13.308 0.011 
MEFSO 20 minutes 6481.977 2 3240.988 5.157 0.024 
Contrast 
Test C Test A 2681.373 1 2681.373 2.349 0.176 
Test C Test B 2929.649 1 2929.649 10.794 0.017 
PEFR 
Sum of sqrs df Mean sqr F sig p 
Test 13869.76 2 6934.881 0.92 425 
Lung*Test 1802.642 12 150.22 1.762 0.071 
FVC 
Sum of sqrs df Mean sqr F sig p 
Test 6159.009 2 3079.504 2.793 0.101 
Lung*Test 1134.551 12 94.546 4.483 0.001 
T-TEST USED.FOR post hoc 
FEF25-75 
Sum of sqrs df Mean sqr F sig p 
Test 43314.18 2 21657.09 3.992 0.047 
Lung*Test 1766.161 12 147.18 1.057 0.408 
Test of within-subjects contrast 
FEF25-75 
TestC Test A 15124.6 1 15124.6 1.576 0.256 
Test C Test B 85888.77 1 85888.77 6.911 0.039 
FEF25-75 3 minutes 7422.077 2 3711.039 4.563 0.034 
Contrast 
Test C Test A 2442.197 1 2442.197 2.179 0.19 
Test C Test B 14678.15 1 14678.15 7.442 0.034 
FEF25-75 7 minutes 9101.516 2 4550.758 5.61 0.019 
Contrast 
Test C Test A 4515.646 1 4515.646 2.638 0.155 
98 
Test C Test B 18202.94 1 18202.94 9.397 0.022 
FEF25-75 10 minutes 5700.919 2 2850.459 4.224 0.041 
Contrast 
Test C Test A 3109.169 1 3109.169 2.877 0.141 
Test C Test B 11394.234 1 11394.23 7.193 0.036 
FEF25-75 20 minutes 6496.145 2 3248.073 6.549 0.012 
Contrast 
TestC Test A 897.996 1 897.996 1.832 0.225 
TestC Test B 5598.149 1 5598.149 11.157 0.016 
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1998 Pollen Counts 
Data collected by K.G. Maybury maybury@essun1.murdoch.edu.au 
Date Pollen/m3 % Pine % Eucalypt % Grass % Compositae % Callitris %Unclassifie d 
26/08/98 12 64 4 9 1 19 2 
27/08/98 17 64 4 14 2 15 1 
28/08/98 4 85 0 0 0 15 
0 
31/08/98 4 9 12 0 0 79 
0 
1/09/98 37 13 27 4 0 52 
4 
2/09/98 34 18 24 0 0 53 
5 
3/09/98 39 51 4 0 0 43 1 
4/09/98 14 58 11 4 0 22 4 
7/09/98 92 9 3 8 7 63 10 
8/09/98 64 13 3 8 13 44 19 
9/09/98 56 29 2 10 3 34 22 
10/09/98 71 48 1 4 1 33 13 
11/09/98 55 90 1 0 0 7 2 
- 14/09/98 75 76 5 2 1 11 
5 
15/09/98 68 68 4 5 5 13 4 
· 16/09/98 144 50 2 14 2 27 6 
17/09/98 332 82 0 1 1 14 2 
18/09/98 79 97 1 0 1 0 0 
21/09/98 77 73 2 2 0 13 9 
22/09/98 59 97 1 0 2 0 0 
23/09/98 29 94 1 0 1 2 2 
24109/98 73 29 1 13 5 37 15 
25/09/98 71 63 9 7 0 14 7 
28/09/98 53 49 1 1 0 42 6 
29/09/98 53 73 1 2 0 19 5 
30/09/98 36 59 3 5 0 21 11 
1/10/98 41 40 1 4 0 46 9 
2/10/98 47 25 2 48 0 18 6 
5/10/98 43 65 2 15 3 10 5 
6/10/98 85 66 1 5 2 22 4 
7/10/98 94 45 3 20 5 19 8 
8/10/98 80 27 2 21 0 41 8 
- 9/10/98 79 33 1 22 0 39 4 
12/10/98 42 55 1 18 0 16 10 
13/10/98 31 37 10 14 0 26 13 
14/10/98 39 31 0 35 1 26 7 
15/10/98 25 27 2 21 0 26 24 
16/10/98 11 24 18 15 0 24 18 
19/10/98 7 26 15 23 0 21 15 
20/10/98 79 3 1 56 4 21 14 
21/10/98 139 2 2 62 4 16 13 
22/10/98 70 5 4 45 5 15 26 
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